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ABSTRACT
Type 1 Diabetic Mellitus (T1DM) patients can develop insulin insensitivity
partially due to the daily requirement of exogenous insulin. Regular exercise has been
shown to improve insulin sensitivity (IS) partially though the increased expression of
skeletal muscle GLUT4 and insulin receptor (IR) content.

Although exercise is

beneficial in increasing IS, exercise presents a problem in the T1DM population, as it
leads to uncontrolled fluctuations in blood glucose (BG) concentrations. This study
examined the effect of aerobic and resistance training exercises on IS and fluctuations in
BG concentrations in T1DM rats. Fifty animals were randomly divided into 5 groups;
control (C), control diabetic (CD), diabetic resistance exercised (DR), diabetic high
intensity aerobic exercised (DH) and diabetic low intensity aerobic exercised (DL). CD,
DR, DH and DL were injected with streptozotocin (STZ) and insulin pellets were
subcutaneously implanted to maintain blood glucose concentrations between 9 and 15
mmol/L. DR climbed a ladder with weights secured to the tail; they performed 6-10
climbs per exercise bout and weights were increased every 3 days to ensure that rats were
lifting maximal weight. They performed exercise bouts 5 days/week for 6 weeks. DH
ran on a treadmill at 27 m/min and 6% grade, 1 hour/day, 5 days/week for 6 weeks. DL
ran on a treadmill at 15 m/min and 6% grade, 1hour/day, 5 days/week for 6 weeks. At 3
and 6 weeks, BG clearance rates in all groups were lower than C (p<0.05). At 6 weeks,
DR, DH and DL also had greater BG clearance rates than CD (p<0.05). IR protein
content in the white gastrocnemius muscle (WG) was elevated in DH, compared to C and
CD (p<0.05), and in DL, compared to C, CD and DR (p<0.05). GLUT4 protein content
in the white portion of the vastus lateralis muscle was increased in DH, compared to CD
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and DL (p<0.05), and in DR, compared to DL (p<0.05), while CD and DL demonstrated
a decrease in GLUT4, compared to C (p<0.05). GLUT4 protein content in the red
portion of the vastus lateralis was elevated in DH, compared to C, CD, DR and DL
(p<0.05). GLUT4 content in DL was lower than in C (p<0.05). GLUT4 protein content
in the WG was increased in DR, compared to CD and DL (p<0.05) and in DH, compared
to CD (p<0.05).

In the DR group, exercise lead to a significant drop in BG

concentrations 1 hour post exercise, when compared to pre-exercise BG concentrations,
at weeks 3 and 6 (p<0.05). At weeks 3 and 6, DH experienced a significant drop in BG
concentrations post-exercise, which restored to pre-exercise values at 45 and 75 minutes
(p<0.05). In week 3, DL experienced a decrease in BG concentrations for 2 hours post
exercise (p<0.05). In week 6 however, DL experienced an increase in BG concentrations
at 30, 105 and 120 minutes post exercise (p<0.05). To conclude, T1DM rodents exhibit
insulin insensitivity, which was alleviated through regular exercise. In addition, different
training modalities lead to different alterations in protein content and exercise induced
fluctuations in BG concentrations. Specifically, aerobic exercise lead to immediate falls
in BG, where as resistance exercise lead to a more gradual fall in BG concentrations.

Keywords: insulin resistance, aerobic exercise, resistance exercise, insulin sensitivity,
insulin receptor, GLUT4, fluctuations in blood glucose concentrations
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CHAPTER 1
1.1 Introduction
Diabetes is a widespread health concern in Canada; it is the fourth leading cause of
death and the global prevalence is increasing daily. According to the International
Diabetes Federation, 177 million people have diabetes and the World Health
Organization estimates that this number will climb to 366 million by 2030 (62). Due to
the significant increase in incidence rates, diabetes is considered an epidemic that
threatens the health of millions of people (47).
Diabetes Mellitus is a metabolic disorder that can be classified into two primary
sub-types, both of which have been linked to a series of health complications including
heart disease, ketoacidosis, kidney failure, stroke, blindness and overall diminished
quality of life (59).

Type 1 Diabetes Mellitus (T1DM) is characterized by the

autoimmune destruction of insulin producing (3-cells located within pancreatic islets,
leading to the inability to produce endogenous insulin. Type 2 Diabetes Mellitus
(T2DM), on the other hand, is identified by insulin resistance, which occurs when
sufficient insulin is endogenously secreted into the blood; however, working tissues of
the body fail to respond efficiently to the insulin hormone. Despite being diagnosed as
mutually exclusive diseases, there is significant overlap between many of the
manifestations of these two diabetes subtypes. For instance, the prevalence of insulin
resistance in T1DM patients has increased; presently, twenty percent of T1DM patients
are insulin resistant (47). Insulin resistant individuals are at three times the risk for the
development of coronary heart disease (CHD) and stroke, while the risk of peripheral
vascular disease is raised to four times in comparison to the normal population (35).
Adolescent T1DM patients are especially vulnerable to the development of insulin
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resistance (45) and diabetes-related cardiovascular complications are exacerbated in these
patients by the presence of both the destruction of p-cells and insulin insensitivity (47).
T1DM is a chronic, progressive metabolic disease that requires the maintenance of
optimal blood glucose values (4mmol/L to 7mmol/L) through the administration of
exogenous insulin (4; 11). Strict maintenance of blood glucose levels is not without its
challenges; fluctuations in glycemia are a common consequence of exogenous insulin
utilization (20). Various factors, such as hormones, neural input, dietary intake and
physical activity, contribute to these glycemic variations (30). In addition, as would be
expected with the chronic use of any drug, the body may become desensitized to the
effects of exogenous insulin and insulin resistance can ensue (41). It has been shown that
when cells are chronically exposed to insulin, the down regulation of insulin handling
proteins can occur, as both insulin receptor (IR) and glucose transport proteins are
reduced (41).
Regular physical activity is an effective method to improve blood glucose control
through an elevation in insulin sensitivity, thereby reducing the overall exogenous insulin
requirement (60). However, it is unclear as to the most suitable form of exercise to
improve glycemic control, as various modalities of exercise are shown to have
differential effects on insulin signaling protein content and glycemic control (12).
Further, T1DM patients have an increased risk of hypoglycemia and hyperglycemia
during and after exercise due to a lack of regulatory control of exogenous insulinmediating effects on glycemic levels, which also appears to be dependent on the modality
of exercise utilized (55). As such, elucidating the ideal modality of exercise that is
capable of minimizing the risks associated with exercise in the T1DM patient is essential
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in order to then determine an appropriate exercise method for T1DM patients in the
attempt to improve insulin sensitivity as well as overall cardiovascular health.

1.2 Physiology of Insulin
The insulin hormone can influence regulatory process within the majority of cells
of the body; however, it effects are of primary significance in the liver, fat, and muscle,
as these tissues play a dominant role in the regulation of metabolic homeostasis (18).
Insulin is synthesized in the fi-cells of pancreatic islets where it is translated as a
preprohormone, preproinsulin (21).

Following the cleavage of a signal peptide,

proinsulin is properly formed acquiring its three dimensional structure (61). Secretory
vesicles then relocate proinsulin to the Golgi apparatus; it is here that proinsulin is
converted to insulin and secreted into the portal vein via exocytosis (21). The secretion
pattern of insulin is pulsative; however, when blood glucose is elevated, insulin secretion
is typically biphasic, represented by an initial fast phase of insulin release responding to
the rise in blood glucose level, pursued by a less intense secretion that is independent of
the initial levels of glucose (46).

The first phase of insulin secretion is mediated

primarily through the stored levels of insulin granules, while the second phase represents
the emission of both stored and newly produced insulin (46).

1.3 Insulin Action
Insulin is the fundamental hormone that normalizes systemic energy supply and
macronutrient equilibrium. Insulin is an anabolic hormone in muscle, as it promotes
glycogen and lipid synthesis, while preventing gluconeogenesis in the liver and the
breakdown of lipids in adipose tissue. During carbohydrate metabolism, as would occur
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following the ingestion of a meal, insulin acts to facilitate the diffusion of glucose from
the blood into in the liver, muscle and adipose tissue via the glucose transporter molecule
(61).
In order to initialize glucose uptake in muscle and adipose tissue, insulin must first
bind to the IR located on the cell surface membrane. The IR is a heterotetramer molecule
that consists of two a- and two (S-glycoprotein subunits, which are linked together
through disulphide bonds (33).

The IR is a tyrosine kinase, acting as enzyme that

mediates downstream activity through the transfer of phosphate groups from ATP to
various target proteins inside the cell. The a subunit is entirely extracellular, and it is this
portion of the receptor to which insulin binds, resulting in a conformational change and
autophosphorylation of its (3 subunits (63). This alteration initiates the catalytic activity
of the receptor, which then results in the phosphorylation of various downstream
intracellular proteins, beginning with the IR substrate (IRS). IRS is a key player in
mediating the intracellular signaling of the IR, serving as a docking station for the
recruitment and activation of different enzymes, ultimately leading To the activation of
the glucose transporter (33).

1.4 Glucose Transporter 4 (GLUT4)
There are thirteen different glucose transporters that facilitate the membrane
translocation of glucose, each of these specific to certain tissue types (24). Glucose
transport is a passive process that requires the use of transporters to assist in its facilitated
diffusion. These glucose transporters are necessary to bring glucose into the cell, as
glucose is a polar molecule and cannot cross the membrane unassisted (61). Skeletal

5

muscle tissue relies heavily on insulin dependent recruitment of glucose transporters and
it is the alteration in these transporting mechanism that many scientist believe to be one
of the critical processes linked to the development of diabetes (42).

GLUT4 is the

glucose transporter located in adipose tissue, skeletal muscle and the heart (49). Skeletal
muscle is the primary site in which glucose is disposed, making it one of the most
significant determinants of insulin sensitivity (28).

Because of this, increasing the

functionality and utilization of GLUT4 provides a potential method to treat diabetes. The
importance of GLUT4 in maintaining homeostasis in these tissues is paramount; 80
percent of the blood glucose that is taken up by these tissues is mediated by GLUT4 (28).
Depending on the energy state of the cell, GLUT4 cycles between active and basal
states.

In the basal state, almost 90 percent of GLUT4 resides in the intracellular

compartments with only 10 percent localized to the cell membrane; however, upon
stimulation, 30 percent of total GLUT4 is redistributed to the cell surface within half an
hour of stimulus (38). Once the stimulus is no longer present, GLUT4 is recycled to non
functional intracellular compartments within twenty minutes (38). GLUT4 is elicited to
the plasma membrane upon stimulation via two very distinct and separate pathways:
insulin-stimulated and contraction-stimulated translocation of GLUT4.

1.4.1 Insulin Stimulating Translocation of GLUT4 in Muscle Cell
Upon binding of insulin, the IR pathway is activated, ultimately leading to the
translocation of GLUT4 to the membrane and the facilitation of glucose transport into the
cell (Figure 1.1). As mentioned above, extracellular insulin binds to the a-subunit of the
IR (IR), leading to autophosphorylation and enzymatic activity of the P-subunit kinase
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activity (step 1), which in turn phosphorylâtes and mediates the localization of IR
substrate-1 (IRS-1) (step 2). The phosphorylated IRS-1 recruits and binds to the p85
subunit of phosphatidylinositol 3-kinase (PI3K) (step3), activating the PI 10 catalytic
subunit of the enzyme.
phosphatidylinositol

The activation of PI3K increases the production of

3,4,5-trisphosphate

(PIP3)

from

phosphatidylinositol

4,5-

trisphosphate (P1P2) (step4), which initiates the recruitment and activation of
phosphoinositide-dependent protein kinase-1, PDK1 (step 5). PDK1 phosphorylâtes and
activates PKB/AKT (step 6), which in turn phosphorylâtes AKT substrate at kilodalton
160 (AS 160) (step 7). The mechanism remains unclear beyond this step; however, it has
been shown that AS 160 targets Rab (step 8) which is a negative regulator of GLUT4
translocation and it is the inhibition of Rab that is believed to lead to the translocation of
GLUT4 to the membrane (36). Rab proteins have been localized to GLUT4-containing
vesicles and are presumed to facilitate their trafficking to and docking of GLUT4 to the
plasma membrane (step 9).

At the cell surface the GLUT4 vesicle fuses with the

membrane (step 10) and glucose is taken up into the cell (step 11) (29).

1.4.2 Contraction Stimulated Translocation of GLUT4 in Muscle Cells
While insulin has been characterized as an important process in the uptake of
glucose, glucose can enter the cell through insulin independent means, such as muscle
contraction-mediated glucose uptake (Figure 1.1) (56). It has been demonstrated that
glucose transport capacity via GLUT4 enhances during exercise; which is primarily
mediated via contraction stimulated mechanisms in working skeletal muscle (56). During
exercise, AS 160, which, as mentioned above, is responsible for the stimulation of Rab-
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mediated translocation of GLUT4, becomes phosphorylated by

5' adenosine

monophosphate-activated protein kinase (AMPK) and not PKB/AKT, as is found in the
insulin-dependent activation of GLUT4. It has been shown that AMPK knockout mice
demonstrate lower levels of AS 160 phosphorylation and glucose uptake during
stimulated muscle contraction (57). Further, mice expressing inactive AMPK show a
decreased translocation of GLUT4 in response to exercise; however, insulin-dependent
translocation of glucose is preserved (65).

Conversely, IR knockout mice cannot

phosphorylate AS 160 via PKB/AKT; however, phosphorylation of AS 160 is preserved
through contractile induced AMPK activation (56).

Such findings demonstrate that

insulin and exercise use distinctive mechanisms to increase GLUT4 transport in muscle;
whereby insulin but not exercise activates P13K and exercise but not insulin stimulates
AMPK.

1.5 Insulin Resistance
Insulin resistance is a physiological condition whereby either endogenous or
exogenous insulin becomes less effective at lowering glucose levels within the blood. In
T1DM patients more exogenous insulin is required in order to avoid elevated blood
glucose levels and subsequent adverse health effects (39). Accompanying complications
associated with the insulin stimulation of GLUT4-mediated uptake of glucose, other
physiological processes are disturbed in the insulin resistant state. For example, in a non
diabetic patient the liver is able to compensate for even small elevations in blood glucose
levels by halting gluconeogenesis; however, in an insulin resistant state, these regulatory
mechanisms are perturbed and the hepatic production of glucose continues, exacerbating
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the current hyperglycemic state (61). Alterations in insulin handling in adipose tissues
also aggravates hyperglycemia, as insulin-mediated uptake and storage of circulating
triglycerides is hindered, leading to an elevation of free fatty acids in the blood (34).
Elevated free fatty acid can further exacerbate insulin dependent blood glucose clearance
(54). Griffin and colleagues (14) have demonstrated that acute elevation of free fatty
acids for 5 hours results in insulin resistant skeletal muscle cells, in vivo.

The

mechanism for which this happens may be through free fatty acid activation of PKC
theta, an insulin signaling molecule (14), ultimately preventing the IR from being
phosphorylated.
In light of these studies, many researchers are now beginning to elucidate the
mechanisms to elevate insulin responsiveness in skeletal muscle which may prove critical
as a therapeutic benefit in the avoidance or improvement of insulin resistance. This stems
mostly from the knowledge that muscle tissue is one of the largest organs in the body
which relies greatly on glucose for energy metabolism. It has been reported that muscle
tissue accounts for 70% of total insulin mediated uptake (53).

1.6 Exercise and insulin resistance
It is well known that exercise is an effective method to reduce insulin resistance
(58). Extensive randomized clinical trials and epidemiological studies have demonstrated
the beneficial outcomes of exercise on improving diabetic states.

For example, the

Finnish Prevention Study demonstrated that exercise consisting of twenty to thirty
minutes per day is associated with a 58% decrease in the progression of impaired glucose
tolerance (58). Exercise not only mediates a reduction in blood glucose levels but it also
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leads to enhance fatty acid oxidation.

It is advantageous to elevate fatty oxidation

capacity in the accompaniment of increased muscle storage of lipids which can be
utilized during exercise; as the storage of fatty acids that is not accompanied with an
increase in fatty acid oxidation capacity can lead to the accumulation of fatty acid
metabolites, such as fatty acid intermediates diacylglycerolceramides. These metabolites
can activate PKC-theta, leading to the phosphorylation of the serine residues and the
inactivation of IRS-1.

By inactivating the IRS-1, downstream constitutes of the IR

pathway are dormant, ultimately preventing the translocation of GLUT4 to the membrane
and subsequent diffusion of glucose into the cell (10).
Stimulation of muscle contraction results in the recruitment of GLUT4 and the
activation of glycogen synthase, ultimately converting unused glucose sources into
glycogen stores (48). In fact, not only does muscle contraction activate AS 160 through a
separate pathway than insulin-dependent GLUT4 translocation, but it also targets a
different reserve of GLUT4 molecules (24). As such, exercise is an effective means to
regulate glucose levels within the blood independently of insulin action allowing T1DM
patients the opportunity to normalize blood glucose without the need for continuous
exogenous insulin therapy.
Initially, it was believed that improvements in insulin signaling sensitivity were not
present until the later stages of long-term aerobic training; however, it has become
evident that the increase in GLUT4 and IR protein occurs promptly (12). Short-term
aerobic exercise programs lead to an increase in insulin sensitivity through the up
regulation of insulin signaling proteins, GLUT4 and IR. Reports have shown that in as
little as 2 to 3 days of participating in various exercise programs, GLUT4 and insulin
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sensitivity increases in skeletal muscle tissue (22). It has also been established that 6
hours per day of swimming stimulated a 200% increase in GLUT4 protein after 2 days of
exercise (50). This increase in exercise-mediated insulin sensitivity, however, appears to
be transient.

Kawanakaet al. (1997) (32) reported that a 5 day, 2 hours per day

swimming exercise demonstrated an 87% and 52% increase in GLUT4 production at 18
and 42 hours post exercise, respectfully. Upon the cessation of the exercise program,
GLUT4 levels returned to control levels by 90 hours. This rapid decline in GLUT4 is
also seen at the end of long-term training. A training program, which consisted of
treadmill running at 32 meters/minute 2 hours per day, 5 times per week for 16 weeks,
showed improvements in insulin sensitivity in skeletal muscle; however, GLUT4 protein
content returned to basal levels by 48 hours following the cessation of the exercise
program (12).

As a result, physical activity should be incorporated into one’s daily

routine to maximize translocation of GLUT4 over extended periods of time.

1.6.1 Exercise Paradox for Type One Diabetics
The literature supports that adherence to various exercise regimes significantly
reduce glycosylated hemoglobin (HbAlc) levels in T1DM patients (3).

HbAlc is

indicative of the time frame of elevated blood glucose levels and is a widely used
diagnostic criterion for diabetes(6). Reducing HbAlc levels reflects the patient’s ability
to control blood glucose levels over the course of months (6). Poor glycemic control is
related to various microvascular complications, such as diabetic retinopathy, nephropathy
and neuropathy, as well as cardiovascular disease (43). To improve these diabetic-related
complications, it is recommended T1DM patients partake in physical exercise on a
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regular basis. In fact, it has been suggested that physical activity of vigorous intensity be
implemented to achieve a maximal oxygen consumption (V02Max) of 55-90% of
maximal heart rate for 20 to 60 minutes, three to five times per week (43). Despite the
known positive benefits of exercise on improving glycemic control, physical activity
levels are much lower in T1DM children in comparison to age matched controls due to
the frequent occurrence of hypoglycemia during or following an exercise bout (43).
Without adequate physical activity, insulin sensitivity cannot be maintained, ultimately
leading to various detrimental health conditions.
Given that T1DM patients administer exogenous insulin through injection or pump,
circulating insulin levels cannot properly fluctuate to account for enhanced insulin
handling nor the recruitment of contraction mediated GLUT4 molecules as a result of
exercise onset (55). In contrast to non-diabetics patients, T1DM patients are unable to
decrease

insulin

secretion

through

glucoregulatory

mechanisms,

resulting

in

hypoglycemia (55).
This exercise-mediated hypoglycemia appears to continue even after the cessation
of exercise. It is believed that the body preferentially replenishes muscle glycogen
storages over those found in the liver; as a result, the liver is unable to release glucose at
a rate to match the peripheral muscle uptake of glucose due to the exercise-mediated
reduction of liver glycogen storage (55).

As such, in the event of T1DM patients

exhibiting any adverse effects of exercise, they are often instructed by health
professionals to cease or refrain from physical activity.
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1.6.2 Effects of various exercise modalities on insulin sensitivity and hypoglycemia.
Various exercise modalities can produce differential responses with respect to
improvements in insulin sensitivity and euglycemia. Uncovering the exercise modality,
which promotes both an increase in insulin sensitivity while preventing hypoglycemia
onset, is essential when implementing an exercise prescription to the T1DM patient.

Aerobic Exercise
It is well established that high aerobic exercise training leads to the enhancement of
glucose metabolism (2; 27), increases in insulin sensitivity in muscle tissue (27) and
improvements in skeletal muscle glucose transport (13; 19; 19; 26; 51; 52). Although
this exercise mode has been viewed as the gold standard to improve insulin sensitivity,
adhering to this type of exercise is difficult for many T1DM patients. As an alternative
exercise mode, a growing population of T1DM patients are participating in low intensity
aerobic physical activity; however, it is unclear as the effectiveness of this lower intensity
modality of exercise in mediating the same beneficial metabolic improvements as high
intensity aerobic exercise (7).
Cortez et al. (1991) conducted a study in which rats were divided into a low and
high intensity aerobic exercise groups (5). It was shown that there were no significant
differences in improvements in glucose clearance rates, plasma insulin and fasting
glucose levels between these two groups. Becker-Zimmermann et al. (1982) showed that
running at a low intensity for 6 weeks, rats demonstrated a reduction in basal insulin
levels and a significant increase in glucose clearance rates as measured by an intravenous
glucose challenge test (IVGTT), a clinical tool used to measure insulin resistance levels
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(1). This research group also showed that when this exercise protocol was administered
in younger rats, the decline in insulin sensitivity could be prevented (1). Despite these
findings, there is still an evidence to suggest that exercise-induced improvements in
insulin sensitivity is dependent on exercise intensity (31).
It has been reported that T1DM individuals who participate in high intensity
aerobic training are less likely to experience exercise-induced hypoglycemia (43). In this
exercise modality, unlike that of lower intensity exercise, muscle tissue relies more
greatly on glucose as a fuel source. Although, the normal balance between glucose
production and uptake is disturbed in the diabetic state (40), the mechanisms of glucose
regulation that are not governed by insulin are preserved (40). For instance, the
sympathetic nervous system activity is elevated during high-intensity exercise which
creates a catecholamine-driven stimulation of hepatic glucose production (17). However,
the rate at which glycogenolysis occurs does not always equal the rate at which glucose is
being taken up by the tissues. Further, in the T1DM patient the metabolic regulatory
processes are not in place to balance and modulate the effects of exogenous insulin and
hypoglycemia can ensue. In attempts to avoid the onset of hypoglycemia, T1DM
individuals often decrease their pre-exercise insulin dose (43) and conversely,
hyperglycemia can then become a concern for these T1DM individuals participating in
high intensity aerobic training. As such, finding the balance between hypoglycemia and
hyperglycemia in T1DM who participate in high intensity aerobic training is often
difficult and dangerous.
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Resistance exercise
In T2DM, resistance exercise produces favorable changes in insulin sensitivity by
increasing glucose storage, increasing glucose clearance from the blood, muscle mass
development and decreasing the required amount of insulin needed to maintain
euglycemia (25). While resistance exercise has not been studied as thoroughly as aerobic
exercise, it has recently been viewed as a therapeutic means to better manage T2DM (64).
Studies have shown that resistance exercise lowers glycosylated hemoglobin (HbAlc)
levels and improves cardiovascular disease risk in individuals with T2DM (37). The first
randomized control trial demonstrated that those who participated in regular moderateintensity resistance exercise had decreased plasma insulin responses to glucose,
indicating that such test subjects were more insulin sensitive (8). Ishii et al. (1998)
demonstrated that glucose enters the cell at a much higher rate in working muscles in
resistance trained individuals, improving insulin sensitivity by 48% (23). Both of these
studies were short in duration (8 and 6 weeks respectively), indicating that insulin
sensitivity can be altered in this short time frame.
While limited studies have been conducted, it has been reported that resistance
exercise improves cardiorespiratory endurance, muscle strength, lipid profile, and
glycemic control in adolescence with T1DM (44).

In addition to these benefits, it has

been reported that resistance training appears to decrease the prevalence of post exercise
hypoglycemia in T1DM individuals (15; 16).

It was found that only one of the ten

participants experienced hypoglycemia-related episodes during the resistance exercise
bout (44). Further, it has been reported that there was a significant decrease in HbAlc
after a 10 week resistance training program in men with T1DM (9). However, it appears
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that such effects require more than one exercise bout, as a single bout of resistance
exercise did not improve insulin sensitivity among untrained and trained T1DM patients
(9)In light of the research, resistance training may be an effective method to improve
insulin sensitivity while helping to maintaining euglycemia.

Since the majority of

available research has been conducted on patients with T2DM, it is necessary to examine
glycemic responses to resistance exercise in the T1DM patients to determine the efficacy
of this exercise modality in this population of patients to potentially alleviate the onset of
diabetic-related complications.

1.7 Summary
It has been demonstrated that exercise enhances glucose management; however,
T1DM patients have an increased risk of fluctuations in blood glucose during exercise
due to a lack of endogenous insulin-mediated control. Minimizing the risks associated
with exercise in a T1DM patient is essential. Presently, an appropriate exercise method
for T1DM to control insulin sensitivity has not been reached. It is known that exercise is
beneficial but it is not clear which modality of exercise is best, whether it be aerobic (low
vs. high intensity) or resistance training. Various modes of exercise training have been
shown to have differential effects on the insulin signaling pathways (12) and result in
distinctive fluctuation glycemic patterns following exercise. As such, further research in
needed examining the effects of various exercise regimens on insulin sensitivity and
blood glucose management post exercise. This work will lead to a better understanding

16

of how a patient with T1DM may benefit from exercise and to elucidate the role of
exercise in improving the prevalence of cardiovascular disease in the T1DM population.

© Glucose

Muscle Contraction

Figure 1.1 Glucose uptake via insulin and contraction stimulated translocation of
GLUT4 in muscle cells Modified from (29). AMPK stands for adenosine
monophosphate-activated protein kinase; aPKC stands for atypical protein kinase C;
AS 160 stands for AKT substrate of 160kDa; ATP stands for adrenosine-5’-triphosphate;
GLUT4 stands for Glucose transporter 4; IRS-1 stands for IR substrate 1; P stands for
phosphorylation; PDK1 stands for phosphoinositide-dependent protein kinase-1; PI3K
stands for phosphatidylinositol 3-kinase; PIP3 stands for phosphatidylinositol 3,4,5trisphosphate; PIP2 stands for phosphatidylinositol 4,5-trisphosphate; PKB/AKT stands
for protein kinase B; PKC-theta protein kinase C -theta; YP stands for phosphorylated
tyrosine.
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CHAPTER 2
2.1 Introduction
Insulin resistance leads to a cluster of disorders, such as, but not limited to, glucose
intolerance, dyslipidaemia, elevated inflammatory markers and disordered uric acid
metabolism (46).

Insulin resistance occurs when normal or high blood insulin

concentrations elicit an attenuated physiological response to the insulin hormone (7).
Insulin resistance is a major contributor to cardiovascular disease; the risk of coronary
heart disease (CHD) and stroke increases three times, while the risk of peripheral
vascular disease is four times greater (28; 29).

Other clinical outcomes include

hypertension, and most commonly, Type 2 diabetes mellitus (T2DM) (39). Although
more frequently associated with T2DM, insulin resistance affects approximately twenty
percent of Type 1 diabetes mellitus (T1DM) patients (35).

Insulin resistance may

develop due to unhealthy lifestyle factors or through the overexposure to exogenous
insulin (31). As a result, it is imperative that T1DM patients prevent the onset of insulin
resistance and, for those who already have the insulin resistance, regain insulin
sensitivity.
A mechanism leading to the development of insulin resistance may be due to the
over compensation of the insulin receptor (IR)-signaling pathway(37). In the continuant
presence of elevated insulin levels (hyperinsulinemia) chronic stimulation of the IRsignaling pathway can leading to the attenuation of the IR function (37). The IR may
also be impaired via lipid accumulation; free fatty acids that are taken up by the tissues
interfere with the IR-signaling pathway (12). Elevated glycemic levels (hyperglycemia)
may also initiate the onset of insulin resistance. It has been shown in vivo that elevated
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levels of the molecule glucosamine, which is a product of glucose metabolism, impairs
GLUT4 translocation to the membrane, resulting in insulin resistance (1).
A disruption in the IR pathway function ultimately reduces the translocation to the
primary glucose transporter, GLUT4, to the membrane, resulting in a decrease in glucose
uptake, and subsequently elevated blood glucose concentrations (42). Independent of
insulin function, however, exercise has been shown to stimulate a contraction mediated
translocation of GLUT4, thereby facilitating the uptake of glucose into the cell and
clearance from the blood (22; 36).

In addition, during and after exercise, the body

becomes more sensitive to circulating insulin, as less insulin is required to stimulate in
the IR pathway (33; 44; 47). As such, it is believed the participation in regular exercise
may be one means to prevent the development of insulin resistance in the T1DM patient.
Although it is well documented that exercise promotes cardiovascular health,
improves insulin sensitivity and prevents the fatty acid accumulation in the T1DM
population, there is an important contraindication to consider. Exercise often leads to
fluctuations in blood glucose levels, causing a T1DM patient ta experience severe
hypoglycemia-related episodes (44). Various exercise modalities can produce differential
responses in blood glucose concentrations.

It has been reported that high intensity

aerobic exercise training leads to the improvement of glucose metabolism and skeletal
muscle glucose transport (11; 16; 17; 23; 40; 41), as well as elevated insulin sensitivity in
muscle tissue (4; 25; 26). While aerobic exercise of high intensity has been shown to
mediate a stimulation of hepatic glucose production via the sympathetic nervous system
(15), the rate at which hepatic glucose is released may not match the increasing rate at
which glucose is being utilized by the working tissues.

As a result, hypoglycemia
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immediately post exercise is a main concern with aerobic exercise particularly at higher
intensity levels (32). Alternatively, low intensity aerobic exercise training has also been
shown to improve insulin sensitivity and does not require similar metabolic demands
associated with high intensity exercise (27). However, without a substantial sympathetic
activation mediating hepatic glucose release, such as that observed during high intensity
aerobic exercise, hypoglycemia may become even more prevalent during and after the
exercise bout (15; 44).
Although resistance training is not as thoroughly studied as aerobic training, this
exercise modality has recently been reported to lead to better management of T2DM in
patients by improving insulin sensitivity (48).

Resistance training in the T1DM

population, however, remains less researched.

Resistance exercise may produce

favorable changes in insulin sensitivity by increasing glucose storage, increasing glucose
clearance from the blood, and increased muscle mass development (24). It is believed
that increases in skeletal muscle mass are correlated with an improvement of glucose
clearance by increasing the glycogen storage capacity (9). In addition to these benefits, it
was found that exercise-induced hypoglycemia was not as prevalent during resistance
exercise in T1DM patients in comparison to aerobic exercise (13; 14; 34).
While several experimental models of T1DM exist, the majority of studies have
utilized the streptozotocin (STZ)-induced diabetic rodent model. Despite the similarities
in diabetes-related complications exhibited in the rodent model and the T1DM
population, experiments are often employed in these studies without the regular
administration of exogenous insulin treatment. Given that physical activity is normally
accomplished under a background of exogenous insulin supplementation it was believed
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that such a model employed utilizing a combination of exogenous insulin and exercise
therapy would better reflect the exercising T1DM population. As such, the objectives of
this study were to examine the effect of various exercise modalities (high intensity
aerobic training, low intensity aerobic training and resistance training) in maintaining or
improving insulin sensitivity while preventing the fluctuations in blood glucose
concentrations associated with exercise in STZ-induced diabetic rodents supplemented
with insulin. Specifically, this study was conducted to determine if either of these
exercise modalities can elicit improvements in insulin sensitivity, GLUT4 and IR protein
content, without inducing a post exercise hypoglycemic response. It was hypothesized
that certain training modalities would lead to more beneficial alterations in insulin
signaling protein content and improvement in insulin sensitivity, while not inducing
fluctuations in blood glucose concentrations following the exercise bout.

2.2 Materials and Methods
Ethics approval
Ethics approval for the participation of rodents in this study was acquired through
the Research Ethics Board of the University of Western Ontario, which is in accordance
with the guidelines of the Canadian Council on Animal Care (Appendix B.l).

Animals
Fifty (8-week old male Sprague-Dawley) rats were obtained from Charles River
Laboratories and housed in standard rat cages that consisted of two rats per cage.
Animals were maintained on a 12-hour dark/light cycle at a constant temperature (20
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±1°C) and relative humidity (50%). Rats were allowed access to standard rat chow and
water ad libitum.

Experimental groups
Fifty rats were randomly assigned to one of five groups as follows: 1) Non diabetic
sedentary control (C; n=10) 2) diabetic sedentary control (CD; n=10), 3) diabetic high
intensity exercise (DH; n=10), 4) diabetic low intensity exercise (DL; n=10), and 6)
diabetic resistance exercise (DR; n=10).

Experimental procedures
Diabetes Induction
Upon arrival rats were housed for a minimum of 5 days to allow the rats to become
familiar with their new surroundings. T1DM was induced by administering 20 mg/kg of
streptozotocin (STZ) via intraperitoneal (IP) injection on 5 consecutive days. Diabetes
was confirmed by measuring two consecutive blood glucose concentrations of greater
thanl8 mmol/L. If diabetes confirmation was not obtained following five injections, the
animals were given subsequent 20mg/kg STZ-IP injections until two readings of
18mmol/L were obtained (Appendix Al).

Following the confirmation of diabetes,

insulin pellets (LinShin, LinPlant - 1 pellet per animal) were implanted subcutaneously
above the abdomen. Insulin pellet dosages were then monitored for 1 week and adjusted
in order to obtain daily non-fasting blood glucose concentrations in the range of 9-15
mmol/L (Appendix A2).
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Exercise Protocol
Prior to the start of the exercise-training program, rodents were familiarized with
the exercise equipment over five sessions. The familiarization period was designed to
allow the rats to become comfortable with their surroundings, while steadily increasing
their ability to perform the exercise program.
DH familiarization consisted of progressive running speeds consisting of 7 m/min
for 10 minutes, 15 m/min for 10 minutes, 21 m/min for 30 minutes and 24 m/min for 10
minutes. For the next five weeks, rats ran 5 days per week for 1 hour per day on a rodent
motor-driven treadmill at a 6 degree slope at a speed of 27 m/min. DL familiarization
consisted of progressive running speeds consisting of 7 m/min for 10 minutes, 11 m/min
for 10 minutes, 13 m/min for 30 minutes and 15 m/min for 10 minutes. For the next five
weeks, rats ran 5 days per week for 1 hour per day on a motor-driven treadmill on a 6
degree slope at a speed of 15 m/min. The exercise intensity chosen for DH and DL was
determined based on earlier research that investigated oxygen uptake in rats at various
running treadmill speeds at approximately 70-80 and 50-60% of V02max, respectfully (3).
Continuous running during the aerobic exercise sessions was encouraged by small blasts
of compressed air that blew on the rats when they either broke a photoelectric beam close
to the rear of the treadmill belt or they came to the absolute rear of the treadmill.
DR rats were required to climb a ladder while wearing a weighted bag secured to
the proximal portion of their tail. The ladder was 1.1m tall on an 80 degree incline and
with 2 cm spacing between rungs.

According to Homberger and Farar(19) these

dimensions allow the rat to complete 8 to 12 “dynamic movements” (limb motion
repetitions) per climb.

Furthermore, this protocol describes an animal model of
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resistance exercise that closely resembles the exercise parameters and physiological
adaptations observed in humans who participate in resistance training(19). During
exercise sessions, rats were allowed to rest for 120 seconds between each climb in a 20
cm3 darkened box placed at the top of the ladder. The familiarization consisted of rats
performing 10 climbs each progressively increasing in resistance with approximately 5%,
15%, 20%, and 35% of their body weight.

Following familiarization, the training

protocol which consisted of 5 days per week for 5 weeks was initiated in which the
weight being carried by the rat was progressively increased using the following regimen.
Maximal lifting capacity was initially determined at every 4 exercise sessions.

To

determine maximal lift capacity, rats were made to climb carrying 75% of their body
weight on the initial climb. Thirty grams of weight was then consecutively added to each
subsequent climb until rats reached exhaustion. Weight carried on the final climb was
marked as the new maximal carrying capacity. The three training days between each
max test consisted of rats carrying 50%, 75%, 90% and 100% of their previously
determined maximal capacity for the first four climbs.

Subsequent climbs were

performed at 100% of their maximal capacity until rats reached exhaustion.

Experimental measures
Body Weights
Body weights for C, CD, DH, DL and DR were measured on each exercise day
immediately prior to the beginning of exercise while blood glucose concentrations and
serum blood collections were completed weekly immediately before and after an exercise
bout. Blood was obtained from the saphenous vein and blood glucose concentration was
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detected using a One Touch Ultra 2 Blood Glucose Monitoring System (Lifescan Canada
Ltd, Burnaby, BC,Canada) and One Touch test strips (Lifescan Canada; range = 0-600
mg/dl). Approximately 100-200 pL of blood was drawn via a needle prick and collected
in microcentrifuge tubes and placed on ice. The samples were then centrifuged at 1500g
for 10 minutes at 4°C. The supernatant of each sample was collected and serum samples
were stored at -70°C for subsequent analysis.

2-Hour and 12-hour Post Exercise Glucose Concentration
Blood glucose concentrations were followed for two hours post exercise at week 3
and week 6; blood glucose concentrations were also recorded 12 hours post exercise at
week 6 of the study. Blood glucose concentrations were recorded immediately before the
exercise protocol was performed. During the 2-hour post exercise examination, blood
glucose concentrations were obtained and recorded immediately after and at 15-minute
increments for two hours post exercise. During the 12-hour post exercise examination,
blood glucose concentrations were obtained and recorded immediately after and at 15minute increments for two hours post exercise. At the 2 hour post exercise time point,
blood glucose concentrations were then taken each hour for twelve hours post exercise.

Intravenous Glucose Tolerance Test
Intravenous glucose tolerance tests (IYGTT) were performed in all five groups at
week 3 (20 ± 2 days) and week 6 (40 ± 2 days) of the exercise-training protocol. Rats
were fasted for approximately 8 to 12 hours prior to the start of testing and did not
perform exercise on the day of their IVGTT. A sterile-filtered dextrose solution (50%

31

dextrose, 50% ddLLO) was injected (1 g/kg) into the tail vein of the conscious rat. Blood
glucose was then measure at 5 and 10 minutes post injection which was then followed by
10-minute intervals measurements for 90 minutes. To ensure proper infusion of dextrose,
animals were required to attain blood glucose measurements >12 mmol/L at five minutes
post injection. If the >12 mmol/L was not reached, food was re-administered until fasting
could be re-implemented and the IVGTT was performed the following day (Appendix
A3).

Insulin Dose
Insulin dose was determined by multiply the number of pellets implanted in the
amount of insulin the pellet secrets per day (2 units of insulin/day) divided by the body
weight of the rat. Insulin pellet dosages were then monitored and adjusted throughout the
course of the study in order to obtain daily non-fasting blood glucose concentrations in
the range of 9-15 mmol/L (Appendix A2).

Tissue collection
Animals were anaesthetized via IP injection of sodium pentobarbital (65mg/kg) and
sacrificed eighteen hours after the last exercise bout. The white and red portions of the
vastus lateralis and gastrocnemius were extracted. Each muscle was frozen in liquid
nitrogen and stored at -70°C.
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Data collection
Western blotting
100 mg of tissue was homogenized in a 1:10 (weight:volume) ratio of
homogenizing buffer (100 mMNaCl, 50mMTris base, O.lmM EDTA, 0.1 mM EGTA and
1% Triton x 100, adjusted to pH -7.5%, 1% phosphotase inhibitor and 1% protease
inhibitor). The homogenates were centrifuged and the supernatant was then collected.
After homogenization, tissues were stored at -70°C until time of total protein
determination and electrophoresis. The Bradford protein assay was used to calculate total
protein concentration in each homogenate sample (6).
Polyacrylamide gels were composed of a 10% acrylamide separating gel and a 4%
acrylamide stacking gel. Homogenates were placed in a 1:1 ratio of sample buffer to
homogenates (0.5 M Tris base, 13% glycerol, 0.05% SDS, 13% 2-beta-mercaptoethanol,
and bromophenol blue). Equivalent total protein amount were loaded into each well. Each
gel contained molecular weight marker to determine the molecular weight of the proteins.
A soleus muscle served as a positive control to permit the standardization of each band
across the various gels.
Electrophoresis was performed and proteins were run at a constant voltage of 150V
for 1.5 hours in running buffer (25mM Tris base, 200mM glycine, and 0.1% SDS, pH
~8.3). Gels were placed in transfer buffer (10% running buffer, 20% methanol, 70%
ddH20) and proteins were electrophoretically transferred to nitrocellulose membranes at
100V. The membranes were blocked in 5% non-fat dry milk (BioRad 170-6404) in Tris
buffered saline (TBS) (10 mMTris, 100 mMNaCl, 0.1 % Tween-20, pH 7.5) for 1.5
hours.

Membranes were then incubated overnight at 4°C with a primary antibody
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specific to either the beta subunit of the IR (rabbit mAb anti IR beta, Cell Signaling 3025,
1:1000), or GLUT4 (rabbit mAb anti GLUT4, Cell Signaling 2213, 1:1000) in TTBS
with 2% non-fat dry milk. After primary antibody incubation, nitrocellulose membranes
were washed in TTBS 3 times for 10 minutes. Membranes were then incubated for 1
hour with horseradish peroxidase-conjugated secondary antibody specific for rabbit IgG
(goat anti-rabbitlgG-HRP conjugate, BioRadl:5,000) diluted in TTBS with 2% non-fat
dry milk. Membranes were washed in TTBS 3 times for 10 minutes and subsequently
imaged using chemiluminescent detection. A luminol-based chemiluminescent substrate
(BioRadWesternC Enhanced Chemiluminescent Kit, 170-5070) was placed on the
membranes, allowing protein bands to become visible. Protein bands were captured
using a BioRadChemidoc XRS imager and optical densities were quantified using
BioRadQuantity One software. Optical densities were normalized to the positive control,
allowing standardization of each band across gels (Appendix A4).

Data Analysis
Body weight, blood glucose concentrations, pre-exercise and post-exercise blood
glucose concentrations, were compared using a two-way repeated measures analysis of
variance (ANOVA) test. When a significant interaction effect was found, a least squares
difference post hoc test was performed. A significant level was set at P <0.05.
The IVGTT area-under-the-curve (AUC) from 0 to 40 min was calculated. IVGTT,
IVGTT AUC, and GLUT4 and IR protein contents were compared via one-way ANOVA
and least square difference post-hoc test. All data are expressed as mean ± SD. All
statistical analysis was performed using SigmaPlot and SigmaStat computer software.
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2.3 Results
Animal weights and training status
Animals in all groups (C, CD, DR, DH and DL) significantly gained weight
throughout the duration of the study (p<0.05) When compared to C, all diabetic groups
demonstrated significant lower body weight gained during the course of the study
(p<0.05) (Fig. 2.1). Mean body weights of CD, DR, DH and DL were not significantly
different than each other at any time point over the course of this study.
The relative weight carried by DR significantly increased throughout the exercise
protocol (p<0.05) (data not shown).

Insulin Resistance measures
Blood glucose concentrations were measured weekly for the duration of the study.
Animals in all diabetic groups had significantly higher blood glucose concentrations than
C at each week following the administration of STZ-treatment during the duration of the
study (p<0.05) (Fig 2.2).
The insulin dose administered to each diabetic group was calculated at week 6 (Fig.
2.3). DH had significantly lower insulin dosage concentrations than all groups (p<0.05).
DL had significantly lower insulin dosage concentrations than C and DR (p<0.05).
An intravenous glucose tolerance test was performed on all animals at week 3 and
week 6 of the exercise protocol (Fig 2.4). At week 3, all groups had significantly slower
blood glucose responses in comparison to C (p<0.05); there were no modifications as a
result of exercise training as no overall difference was observed among CD, DR, DH or
DL. At week 6, all groups had significantly faster blood glucose responses than CD
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(p<0.05). All diabetic groups had significantly slower blood glucose responses than C
(p<0.05) and these responses were not different across the exercise diabetic groups as no
significant differences were found.
The IVGTT area under the curve (AUC) was analyzed at week 3 and week 6 of the
exercise training program (Fig.2.5). At week 3, all diabetic group had significantly
greater IVGTT AUC than C (p<0.05). At week 6 all diabetic groups had significantly
greater IVGTT AUC than C (p<0.05), while CD is had a significantly greater IVGTT
AUC in comparison to C, DR, and DL

Protein Content
White (WG) and red (RG) portions of the gastrocnemius and vastus lateralis (WV
and RV, respectively) muscles were used for detection of the IR and GLUT4 protein
content. IR protein content was not significantly different between all groups in the WV,
RV and RG (Fig. 2.6A,B and D). In the WG, however, DL had significantly more IR
protein than C, CD and DR (p<0.05), while the DH had significantly more IR protein
content than C and CD. (Fig.2.6C).
GLUT4 protein content in the WV was significantly lower in CD, when compared
to C and DH (p<0.05), while DL had significantly less GLUT4 protein content than C,
DR and DH (p<0.05) (Fig.2.7A). In the RV, DH had significantly more GLUT4 protein
than C, CD, DR and DL (p<0.05), while DL had significantly lowerGLUT4 protein
contentin comparison to control (Fig.2.7B).

In the WG, DR had significantly more

GLUT4 protein than CD and DL (p<0.05), while DH had significantly more GLUT4
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protein content than CD only (p<0.05) (Fig2.7C). There were no significant differences
in GLUT4 protein content between groups in the RG (Fig.2.7D).

Exercise induced fluctuations in blood glucose
Blood glucose concentrations were examined in DR, DH and DL for 2 hours post
exercise at 3 and 6 weeks of exercise training (Fig. 2.8A,B and C) and for 12 hours post
exercise at 6 weeks of exercise training (Fig. 2.8D). DR demonstrated no significant
difference between blood glucose concentrations in week 3 and week 6, while DH and
DL demonstrated significantly higher blood glucoses in week 6 in comparison to week 3
(p<0.05). At week 3, DR experienced a significant drop in blood glucose concentrations
at 60 minutes, 75 minutes, 90 minutes, 105 minutes, and 120 minutes post exercise,
compared to pre exercise values (p<0.05). At week 6, the significant drop in blood
glucose concentrations was not seen until 75 minutes and continued until 120 minutes
post exercise bout (Fig. 2.8A) (p<0.05).
At week 3, in comparison to pre exercise values DH demonstrated a significant
drop in blood glucose concentrations immediately after exercise which continued until 75
minutes post exercise bout (p<0.05). At week 6, DH demonstrated a similar drop in
blood glucose concentrations immediately after exercise but returned to pre exercise
values by 45 minutes post exercise bout (Fig. 2.8B) (p<0.05).
At week 3, DL blood glucose concentrations were significantly lower than pre
exercise values immediately post exercise and did not up to 2 hours post exercise
(p<0.05). In contrast, at week 6, blood glucose concentrations did not drop below pre
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exercise values but were significantly higher at 30 minutes, 105 minutes and 120 minutes
after the exercise bout (Fig 2.8C) (p<0.05).
At week 6, there was no difference in blood concentrations observed beyond two
hours post exercise.

DR, DH and DL returned to pre exercise blood glucose

concentrations by 3 hours post exercise (Fig 2.8D).
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8

Weeks

Figure 2.1.Weekly body weights. Body weights are expressed as mean ± SD in each
group. STZ, IP, EX indicates the beginning of the diabetes induction, the insulin pellet
insertion and the initiation of the exercise protocol, respectfully, as described in the
methods section. All groups gained weight over the course of study. When compared to
C, all diabetic groups demonstrated significantly lower body weights throughout the
study. An asterick (*) indicates a significant difference between all other groups, based
on the interaction effect shown by the two way ANOVA (p<0.05).
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Week
Figure 2.2.Weekly blood glucose concentrations. Weekly blood glucose concentrations
in all groups are expressed as mean ± SD. STZ, IP, EX indicates the beginning of the
diabetes induction, the insulin pellet insertion and the initiation of the exercise protocol,
respectfully, as described in the methods section. All diabetic groups were significantly
higher than C following STZ administration at each following week throughout the study.
An asterick (*) indicates significant difference between all other groups, based on the
interaction effect shown by the two way ANOVA (p<0.05).
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Figure 2.3.Insulin dose. Insulin dose, expressed as mean ± SD, was calculated at week 6.
DH had significantly lower insulin dosage concentrations than all other groups. DL had
significantly lower insulin dosage concentrations than C and DR. b= different than CD,
p<0.05; c= different than DR, p<0.05; e= different than DL, p<0.05.
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Figure 2.4. Blood glucose clearance curve following an intravenous glucose infusion. A.
IVGTT results at week 3 are expressed as a mean ± SD in each group. An asterick (*)
indicates a significant difference between all other groups, based on the interaction effect
shown by the two way ANOVA (p<0.05). B. IVGTT results at week 3 are expressed as a
mean ± SD in each group. A number sign (#) indicates a significant difference between
all other diabetic groups, based on the interaction effect shown by the two way ANOVA
(p<0.05).
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Figure 2.5. IVGTT area under the curve. A. At week 3, area under curve from 0 - 4 0
min, expressed as mean ± SD, was significantly greater in all diabetic groups, when
compared to C. a= different than C, p<0.05. B. At week 6, area under curve from 0 - 4 0
min, expressed as mean ± SD, was significantly greater in all groups, when compared to
C. C, DR and DL had significantly less IVGTT AUC than CD. a= different than C,
p<0.05; b= different than CD, p<0.05.
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Figure 2.6. IR protein content. Total IR protein content, expressed as mean ± SD, was
analyzed in the white and red portion of the gastrocnemius and vastus lateralis muscles.
A. IR protein content in WV did not demonstrate a significant change between groups.
B. IR protein content in RV did not demonstrate a significant change between groups. C.
DL had significantly more IR protein content in the WG than C, CD and DR, while DH
had significantly more IR protein content than C and CD. D. IR protein content in the RG
did not demonstrate a significant change between groups.a= different than C, p<0.05; b=
different than CD, p<0.05; c= different than DR, p<0.05.
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Figure 2.7. GLUT4 protein content. A. Total GLUT4 protein content, expressed as mean
± SD, was analyzed in the white and red portion of the gastrocnemius and vastus lateralis
muscles. A. GLUT4 protein content in WV was significantly lower in CD, when
compared to C and DH. B. DFI had significantly more GLUT4 protein content in RV
than all other groups. When compared to C, DL had significantly less GLUT4 protein
content. .C. DR had significantly more GLUT4 protein content in WG than CD and DL.
DH had significantly more GLUT4 protein content, when compared to CD. D. There
were no significant differences in GLUT4 protein content between groups in RG.a=
different than C, p<0.05; b= different than CD; c= different than DR, p<0.05; d= different
than DH, p<0.05; e= different than DL, p<0.05.
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Figure 2.8. 2 hour post exercise blood glucose concentrations. Blood glucose
concentrations were examined in (A) DR (B) DH and (C) DL for 2 hours post exercise
and were are expressed as a mean ± SD in each group. DR demonstrated no significant
difference between in post exercise blood glucose concentrations at week 3 and week 6;
DH and DL demonstrated significantly higher blood glucoses in week 6 vs. week 3
(p<0.05). An asterick (*) indicates a significant difference between groups, based on the
interaction effect shown by the two way ANOVA (p<0.05). A number sign (#) indicates a
significant differences between blood glucose concentrations at pre exercise and specific
time points in week 3 based on the post hoc tests are shown as(p<0.05). A percentage
sign (%) indicates a significant differences between blood glucose concentrations at pre
exercise and specific time points in week 6 based on the post hoc tests are shown
as(p<0.05). D. 12 hour post exercise blood glucose concentration.
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2.4 Discussion
One of the most effective means to prevent the onset of insulin resistance is through
the participation in regular exercise (45). Insulin resistance is an emerging problem in
the T1DM population; approximately 20% of all T1DM patients display insulin
resistance (35).

Although the relationship between exercise and insulin sensitivity is

quite evident, many T1DM patients do not exercise. In fact, T1DM patients have lower
rates of physical activity than non-diabetic individuals, due to the risk of exercise induced
fluctuations in blood glucose (32).
Insulin resistance can be caused by a number of metabolic malfunctions, including
hyperglycemia, hyperinsulinemia and free fatty acid accumulation (1; 10; 12; 30; 43).
All such metabolic imbalances lead to defects in the IR signaling pathway at post
receptor target points (46).

As such, it is believed that these alterations in insulin

signaling over time in the T1DM patient, lead to the requirement of greater insulin
dosages to establish the same metabolic effects of the exogenous hormone (31).
It was demonstrated in this study that diabetic rodents in a chronic sedentary state
led to the development of insulin resistance. At the half point of the study (week 3), all
diabetic groups demonstrated lower glucose clearance rate and an increase in IVGTT
AUC, compared to C. A decrease in the rate in which glucose is cleared is an indication
that glucose cannot be deposited to the tissues at a rate comparable to that of a non
diabetic animal(5).

At six weeks, however, CD continued to become less insulin

sensitive, where exercise regardless of modality appeared to attenuate insulin resistance
as demonstrated by an increase in glucose clearance rates. In addition, DR and DL
demonstrated significantly lower IVGTT AUC than CD indicating that blood glucose
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concentrations remain higher for a longer period of time following the IVGTT challenge.
While DH did not have a significantly lower IVGTT AUC (p=0.054) than CD, this group
required a significantly lower insulin dosage in comparison to CD, DR and DL, in order
to maintain blood glucose concentrations at the target range (9 to 15mmol/L). Similarly,
DL had a significantly lower insulin dose than CD and DR suggesting that aerobic
exercise was more beneficial than resistance exercise and sedentary activity to reduce the
daily insulin requirement. Further, DH and DL required a lower insulin dosage to
produce similar glucose clearance profiles during the IVGTT which may suggest
enhanced insulin sensitivity in this group compared to CD or DR. These results are in
line with those of previous studies that demonstrate that both high and low intensity
aerobic training programs increase insulin sensitivity (2; 8; 25; 27; 27).
It is important to note that insulin sensitivity was significantly improved in the
rodents that resistance trained. While the requirement of insulin dosages was similar, DR
cleared glucose at a significantly faster rate than CD. Houmard et al. (20) found that
exercise intensity had little effect on insulin sensitivity, rather, it was the duration of the
aerobic exercise that was the major determinant of glucose clearance rates. It would seem
that when comparing two modalities of exercises of the same duration, the exercise
protocol with the greatest intensity would have the greater effect on the insulin dose
requirements. In the current study, DR participated in roughly one-third the duration of
the aerobically exercised animals and therefore this would suggest that if the duration of
their exercise sessions were lengthened, DR may have improved their insulin dose
requirement to values similar to DH and DL.
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A potential explanation as to why aerobic training lead to a significant increase in
insulin sensitivity in comparison to CD, could be due to an elevation in the skeletal
muscle content of IR and GLUT4 protein content.

DH demonstrated a significant

increase in IR protein content in the WG muscle, compared to both sedentary groups, C
and CD. Further, GLUT4 protein content also increased in DH, compared to CD, in WV,
RV and WG.

Previous studies found that an increase in glucose clearance rates is

associated with an increase in IR protein content (18) and would here suggest that an
increase in GLUT4 protein may also allow for a greater rate of glucose deposits in the
muscle.
Although low intensity aerobic training led to an increase in insulin sensitivity
concomitant with a decreased insulin dose requirement, compared to CD and DR, insulin
doses were still higher than DH. Interestingly, DL displayed a significantly greater IR
protein content in the WG (similar to the levels observed in DH); however, GLUT4
protein content was significantly lower compared to DH in WV, RV and WG.

A

possible explanation for these discrepancies could be due to the differential effect of
various exercise modalities on separate pathways mediating GLUT4 translocation.
Perhaps low intensity exercise increases insulin sensitivity through an elevation of IR in
certain tissues, but without a concomitant increase in GLUT4 protein content, the
contraction mediated translocation of GLUT4 pathway would not likely be altered. In
this event, the muscle must rely primarily on the insulin mediated translocation of
GLUT4 pathway to uptake glucose into the cell. In line with this idea, DR demonstrated
an increase in insulin sensitivity but IR protein content was significantly decreased and
unchanged in the WG and WV, respectively, while GLUT4 was significantly increased in

57

both the WV and WG. This may indicate that resistance exercise favors the contraction
mediated translocation of GLUT4 pathway which in turn causes the elevation of GLUT4
protein content in these muscles.
The second component of this study was to examine the influence of exercise
modality on glycemic fluctuations post exercise. At week 3, both the DH and DL
demonstrated a significant drop in blood glucose concentrations immediately post
exercise which returned to pre exercise values by 2 hours. In line with these results, as
well as others (26), aerobic exercise leads to an increase in insulin sensitivity as well as
insulin signaling protein content post exercise which could elicit the continuous uptake of
blood glucose even following the completion of the exercise.

Further, rats were

implanted with a continual release insulin pellet mimicking a T1DM patient utilizing a
constant dosage of insulin. In otherwise healthy patients, the normal release of insulin
from pancreatic islets is continuously regulated through both neural and humoral factors
to match the release of insulin to the metabolic state (32).

Without this regulatory

mechanism, T1DM patients have not only an elevated insulin sensitivity but a steady
output of circulating insulin, which is not under the influence of negative feedback
control, leading to a greater blood glucose clearance rate (44).
While the drop in blood glucose levels following exercise is well documented (44),
what was an interesting finding of the current study was that glycemic responses at 6
weeks of training were different that at 3 weeks. Particularly, the DL, which
demonstrated an elevated blood glucose concentration after exercise at week six in
comparison to their pre exercise blood glucose values. This was a surprising result, given
that the tissues were increasingly sensitive to insulin and it is unlikely that a strong
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sympathetic response was present at this level of exercise intensity (44). One explanation
for these results could be that there was a regeneration of pancreatic control following the
6 weeks of exercise training. It has been shown that T1DM rodents have a significantly
higher functioning pancreatic a cells responsible for the release of glucagon, than non
diabetic controls (21), leading to an increase in plasma glucagon (38). These findings
may support the role of low intensity training in improving the mechanisms involved in
glucagon-mediated breakdown of glycogen in the liver in order to alleviate the fall in
blood glucose concentrations following exercise. While DH displayed the same
immediate fall in post exercise blood glucose concentrations between weeks, DH
returned to normal blood glucose concentrations faster in week 6 in comparison to week
3. Similar improvements in a cells function may account for this adaptation; however,
increases in glucagon release may not be able to compensate for greater energy
expenditure seen in this type of exercise modality thus preserving the immediate drop in
blood glucose level.
In contrast to DH and DL, DR experienced a gradual decline in blood glucose
which returned to pre exercise values by approximately 4 hours.

As well, DR

demonstrated no differences between week 3 and 6 in their glycemic responses,
indicating that an adaptive response was not present following this modality of training.
This gradual decline however may be beneficial to T1DM patients, as it does provide
ample time to combat the fall in blood glucose following exercise. Such precautionary
measures as carbohydrate ingestion or the reduction in insulin dosage levels could
mitigate this observed hypoglycemia onset.
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Unlike the other exercise modalities within this study weights were continually
added to DR to ensure that progressively increasing work rates were being performed.
This in turn elevated the stress of the exercise and may elicited the release of
catecholamines; resulting in the stimulation of glycogenolysis and an increase in blood
glucose concentrations (15). As such, progressive increases in exercise intensity may
prove to be a means to elicit a sufficient catecholamine response during exercise,
preventing the immediate fall in blood glucose concentrations that was present in the
aerobically exercised animals.

2.5 Limitations
In this current study, there are several limitations that need to be acknowledged.
First, it would be advantageous to monitor the amount of food that the rats consumed. It
would be interesting to see if specific exercise modalities caused a significant increase in
food intake. If there were differences present between groups, the impact of diet on
various measures (such as weight gain and serum lipids) could be examined. Second,
providing the animals with free wheels inside their cages would allow for the
quantification of exercise ad libitum. Future studies may with wish to address these
limitations.

2.6 Conclusion
The prevalence of insulin resistance is increasing in the T1DM population.
Exercise is an effective therapy for T1DM patients to use in order to regain insulin
sensitivity; however, prescribing exercise to this population is difficult. T1DM patients
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often experience fluctuations in blood glucose levels caused by the exercise. As such,
this study aimed to uncover an exercise modality that would both improve insulin
sensitivity while preventing exercise-induced hypoglycemia.
This study found that T1DM rodents, in the absence of exercise, demonstrated
insulin resistance, while T1DM rats that exercised had significant improvement in their
insulin sensitivity. Further, both high and low aerobically exercised rats had a decrease
insulin dose requirement and high aerobic exercise elicited the greatest improvement in
IR and GLUT4 protein content. In regards to stabilizing blood glucose concentrations
post exercise, all groups brought forth varying glycemic profiles. Resistance exercise
caused a more gradual fall in blood glucose concentrations, while aerobic training caused
a drastic drop in blood glucose concentrations immediately following the exercise bout.
However, in contrast to DR, both DL and DH demonstrated improvements in the return
to pre exercise values by 6 weeks of training, suggesting that glycemic adaptations to the
exercise training occurred within these animals.
Considering these results, it may be advantageous to examine how insulin
sensitivity and exercise induced blood glucose concentrations are affected by a combined
exercise protocol. High intensity aerobic exercise proved to increase insulin sensitivity
concomitant with a decrease in insulin dose requirement.

Resistance exercise, on the

other hand, demonstrated an elevation in insulin sensitivity and a delayed exercise
induced drop in blood glucose concentrations in comparison to the immediate fall in
glucose levels evident in the aerobically trained animals. Further, DR animals did reduce
the requirement of insulin dosage but did demonstrate different insulin signaling protein
content profiles than the aerobically trained animals, suggesting an enhancement of the
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contraction-mediated GLUT4 pathway. As such, combining aerobic and resistance
exercise into one exercise protocol may produce both a significant increase in insulin
sensitivity and protein content, but also minimize the risk of post exercise hypoglycemia.
The current study can serve as the foundation in which further research can be built
upon. Ultimately, this line of research aims to promote the health of people with T1DM
by providing them with information necessary to take control over their diabetes and
improve their overall health. It is with hope that in the future that T1DM patients will
better understand the therapeutic role of exercise and the importance of selecting
modalities of exercise that reduce the incidence of detrimental fluctuations in glycemic
control.
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APPENDIX A
A l. Streptozotocin induction protocol
REVISION DATE: 28/06/2011
PURPOSE:
To induce Type I diabetes in rats
MATERIALS:
Gloves
Lab Coat
Streptozotocin (STZ)
5X Stock Citric Acid/Citrate Buffer
Anhydrous Citric Acid
Sodium Citrate Dihydrate
MilliQ Deionized Water
13M HC1
3 Falcon Tube
Sterile Filter
EQUIPMENT:
Biological Safety Cabinet
Weigh Scale
pH Meter
PROCEDURE:
Preparing 5X Citric Acid/Citrate Buffer
1. For a pH 4.6 buffer at 765 raM (5X stock solution), in a beaker, Add
1. 13.8 g Anhydrous Citric Acid (Sigma)
ii. 23.8 g Sodium Citrate Dihydrate (Sigma)
Mix into iii. 175 ml of MilliQ water
The pH should be at 4.6, Add HC1 or NaOH to adjust (do not over-shoot pH)
2. Once the proper pH is obtained, add MilliQ water until you are close to the 200 ml
mark (pH will move slightly). If satisfied with the pH, adjust volume in a 250 ml
graduated cylinder and filter in a 0.2pm filter.
3. Store at room temperature. This is your 5X stock solution.
Making up Streptozotocin (STZ) for Injection
**NOTE Animals should be pre-weighed prior to making up STZ to ensure accurate
amounts of STZ to be prepared.
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1. Using pre-made buffer, put 1 ml of buffer in a 50 ml Falcon Tube and add 4 ml of
distilled water filtered through a 0.2pm syringe filter. Check the pH. This gives you
a working concentration of 153 mM
2. The desired pH is between 4.5-4.7. Under the fume hood, add 1 drop at a time of
concentrated HC1 to the buffer, checking pH in between until desired pH is reached.
3. Once pH is reached, add 1 ml distilled water (sterile filtered through a 0.2pm syringe
filter as before). If pH is below 4.5, restart.
4. Weigh out an appropriate amount of STZ for the number of animals (see calculations
below) that will be injected in a 15 minute time frame.
Ex. Rats will be injected at 20mg/kg, so for 10 animals at an ideal weight of 200g
(avg. weight of rats to be injected), you will require a minimum of 40mg.
20mg/kg X 0.2kg = 4mg per animal
The amount of STZ weighed out should be more than the minimum as some solution
will be lost in filtering. (4mg (per animal) X 12 rats = 48mg total (0.048g)
5. Dissolve the STZ into buffer (keeping in mind a comfortable injection volume).
Shake to dissolve powder (approx, lmin). Sterile filter using a 0.2pm syringe filter.
Ex. 48mg STZ 3 mL buffer = 16mg/mL solution
4mg

16mg/mL solution = 0.25m

6. STZ is time dependent and must be used within 15 minutes
Injecting and Follow-Up of the Animals
1. Promptly inject each rat with the solution (intraperitoneal) at a dosage rate of
20mg/mL (in this example, 0.25mL). Do not use anymore STZ solution more than 15
minutes after it has been dissolved in the sodium citrate buffer.
2. Dispose of any container having come into contact with the STZ (in either powder or
dissolved form) into a biohazardous waste receptacle. Dispose of needles into a
sharps container.
3. Return injected rats to their cage. Record the date of STZ injection.
4. Repeat this procedure the following day.
5. Check blood glucose daily. Diabetes is achieved with two non-fasting blood glucose
readings of >18 mmol Diabetes should be achieved after 5-8 injections (i.p.
20mg/kg)

Reference:
Low dose STZ induction protocol. Animal Models of Diabetic Complications
Consortium AMDCC Protocols.2003
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A2. Insulin pellet insertion protocol
MATERIALS:
LinShinLinPlant Insulin Pellet (LinBit pellet for mouse)
Rat anesthetic mix - ketamine/domitor (or mouse anesthetic mix - ketamine/xylazine)
Ampicillin
Sterile water
lml syringe with 25 g needle
10% providone-iodine solution
gauze (or swab)
Stylet
Tissue forceps
Scalpel handle and blades (or scissors)
Silk suture
Needle drivers
Isofluorane
EQUIPMENT:
IsofluoraneAnaesthetic Machine
Triple beam scale (or Mettler balance)
Clippers
Heat lamp
Special Safety:
Must don lab coat and gloves before handling rodents. Any bite or scratch that breaks the
skin must be thoroughly scrubbed with soap and water. If infection results, report to
Occupational Health.
Procedure:
Pellet implantation:
1. Anesthetize the animal using the isofluorane machine by placing it in the chamber.
For a mouse, set to 1.5-2% Isofluorane and 1 L O2 , or for a mouse set to 1%
isofluorane and 1 L 02. Open the stopcock valve so gas reaches the chamber. Keep
in chamber until the animal is unconscious.
2. Remove the animal and place its nose in the nose cone, maintain settings as above,
for a rat reduce the isofluorane to 1-1.5% Isofluorane to maintain unconsciousness.
3. Shave the area where the pellets are to be implanted.
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4. Using gauze (or a swab) apply 10% providone-iodine solution to the skin to disinfect
the site of insertion.
5. Hold the skin with forceps and make a subcutaneous incision.
6. Cleanse a 12g trocar with 10% providone-iodine solution and insert it through the
puncture site to a depth of at least 2 cm (1.5 cm for mouse).
7. Using forceps, briefly immerse the pellet in 10% providone-iodine solution and insert
into the subcutaneous region.
8. Use 1 pellet for the first 350g body weight.
9. Pinch the skin closed after the last pellet is inserted. Place a drop of 10 % providoneiodine solution over the opening.
10. Close the incision by suturing
11. Place the animal under a heat lamp and monitor until it recovers from anesthesia.
12. Record on the cage card that insulin pellets have been implanted.

Pellet removal:
1. Anesthetize the animal as described above for implanting the pellet. If pellets are
being removed during transplants, remove at end of procedure.
2. Shave and palpate the area of implantation to locate pellets. Sterilize this area by
applying 10% providone-iodine solution.
3. Using a scalpel (or scissors), make an incision through the skin superficial to the
location of the pellets.
4. Using forceps, remove the pellet. Some connective tissue may need to be cut away
using scissors. Discard the pellet.
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5. Close the incision by suturing.
6. Place the animal under a heat lamp and monitor until it recovers from anesthesia.
7. Record on the cage card that the pellets have been removed.

References:
1. http://www.linshincanada.com
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A3. Intravenous Glucose Tolerance Test protocol
MATERIALS:
15 ml Falcon tube
D glucose
Distilled water
0.2 um syringe filter
5 ml vacutainer
Emla Cream
3 ml syringe
27 G needles
Green drape
Microcentrifuge tubes
Vaseline
30 G needles
Gauze squares
EQUIPMENT:
Mettler balance
Biological safety cabinet
Heat lamp with 175 w bulb
Glucometer (Freestyle mini)
Timer

Special Safety:
Must don lab coat and gloves before handling rats. Any bite or scratch that breaks the
skin must be thoroughly scrubbed with soap and water. If infection results, report to
Occupational Health.

Procedure:
Fasting Rats:
1. At 21:00 on the night before the IVGTT is to be performed, transfer the rats to a clean
cage.
2. Transfer the rat’s tube to the new cage, ensuring that there is no food inside of it.
3. Place a fresh lid on the cage, with no food on it. Put a water bottle on the lid.
4. When leaving the animal quarters, return the light switch to the auto position.
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Glucose preparation:
1. On the morning of the IVGTT, dispense 5ml distilled water into a clean 15 ml conical
Falcon tube.
2. Weigh out 5 g of D-glucose, and add it to the tube containing the sterile water.
Dissolve by vortexing to result in a 50% glucose solution.
3. In a biological safety cabinet, sterilize the glucose solution using a 0.2 um syringe
filter.
4. Transfer the sterile glucose solution to a 5 ml vacutainer.
Intravenous Glucose Tolerance test (IVGTT):
1. Place the cage containing the rat under a heat lamp. Remove the tube from the cage,
and provide water for the rat. Warm the rat in this manner for 10 minutes.
2. Remove the rat from the cage and scrub the tail using soap and water.
3. Measure and record the rat’s weight.
4. Obtain a baseline blood glucose reading and collect a baseline serum sample.
5. Return the rat to the cage and warm for an additional 20 minutes.
6. Place the rat’s tail in a container of warm tap water for 30-60 seconds.
7. One person should dry the tail and restrain the rat by wrapping it in a green drape so
the tail is exposed. Occlude the tail vein by applying pressure.
8. Using a 3 ml syringe and a 27 G needle, a second person will draw up the 50%
glucose solution at a dose of 2 ml/kg (=1 g/kg). Locate the tail vein and draw back on
the plunger to ensure that the needle is within the vein.
9. The restrainer will now release occlusion while the glucose solution is injected. Draw
back the plunger a couple of times during the injection to ensure that the needle
remains located within the vein.
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10. Start the timer and return the rat to its cage. Continue warming it for the duration of
the IVGTT.
11. Check and record the blood glucose values for the rat at 5, 10, 20, 30, 40, 50 and 60
minutes post glucose challenge. If by 60 minutes, the blood glucose value hasn’t
returned to baseline, continue to check every 30 minutes until it does so (up to a
maximum of 180 minutes).
12. Upon completion of the IVGTT, remove the rat from under the heat lamp and return
the tube to the cage. Place food on the wire lid of the cage, and ensure that the rat has
access to water.
13. Note on the cage card that an IVGTT has been performed.
Reference:
Straczkowski M et al, The effect of exercise training on glucose tolerance and skeletal
muscle triacylglyerol in rats fed with a high-fat diet. Diabetes and Metabolism (2001) 21
pl9
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A4. Western Blot protocol
Proteins tested:
GLUT4, Insulin Receptor
Tissues tested:
White and Red Gastrocnemius; White and Red Vastus Lateralis
Before you begin
Make sure you have the following stock solutions:
10X Tris buffered saline (TBS; 100 mMTris pH 7.5, 1 M NaCl)
10X Running buffer (250 mMTris (don’t adjust pH), 1.92 M Glycine, 1% SDS)
Acrylamide solution1(30% acrylamide, 0.8% bis-acrylamide)
Separating gel buffer2 (1.5 M Tris pH 8.8, 0.4% SDS)
Stacking gel buffer5 (0.5 M Tris pH 6.8, 0.4% SDS)
Sodium dodecyl sulphate (SDS) solution3 (10% SDS)
2X Laemmli SDS-PAGE sample buffer 4 (4% SDS, 20% Glycerol, 10% (3mercaptoethanol, 0.015% bromophenol blue, 0.125 M Tris pH 6.8)
Water-saturated butanol
Separating gel
1.
2.
3.
4.

Take samples, positive controls, “ladders”, etc and allow them to thaw on ice.
Clean mini-gel plates with 70% ethanol before use.
Assemble gel cassettes, and look for leaks with water if desired.
Prepare separating gel in a small beaker with continuous stirring.
a. A 10% gel is best for GLUT4 and Insulin Receptor; the voluihesAhere are for
eight 1.5 mm thick 10% polyacrylamide gels.
b. Prepare a 10% ammonium persulfate (APS) solution; it is important to prepare
this fresh every time. Measure out 50 mg of APS powder, place into a 1.5 mL
Eppendorf tube, and add 450 pL of double distilled water (dd^O ).
c. Add 31.984 mL of ddH20.
d. Add 26.667 mL of Acrylamide solution1; begin to stir.
e. Add 20 mL of Separating gel buffer .
f. Add 800 pL sodium 10% SDS3.
g. Let stir for a minimum of 10 min.
h. Add 500 pL of 10% APS solution and 50 pL of tetramethylethylenediamine
(TEMED) simultaneously and let stir for about 20 seconds.
5. Quickly pour the gel into each cassette with a Pasteur pipet up to about 1.5 cm from
the top of the “short” plate.
6. Try to remove most bubbles by tipping apparatus and/or soaking them up with filter
paper.
7. Immediately, but very carefully and gently, overlay each gel with about 1 cm of
water-saturated butanol.
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8. Allow gel to polymerize for 30 - 60 min (longer is better).
a. Tip: keep some of the gel in the Pasteur pipet. This will tell you if the gel is
successfully polymerizing.
b. Tip: Do not touch the apparatus as the gel is polymerizing to ensure that it
polymerizes evenly.
9. While this is taking place, continue preparing your samples:
a. There are two methods to preparing, and subsequently loading, samples. In
both methods, equal amounts of total protein from each sample will be loaded.
The difference is whether equal volumes, and thus equal protein
concentrations, will be loaded.
b. Method 1:
i. Once thawed, mix samples (eg. by vortexing), and pipet appropriate
volumes into a second set of labelled tubes.
ii. Add an equal volume of 2X Laemmli SDS-PAGE sample buffer 4 to
each tube
iii. Each tube should now be a 1:1 mixture of homogenized sample to the
sample buffer.
c. Method 2:
i. Exactly as method 1, mix samples and pipet appropriate volumes into
a second set of labelled tubes.
ii. However, equalize volumes across the samples by topping up with
homogenizing buffer.
iii. Then add a volume of 2X Laemmli SDS-PAGE sample buffer4 equal
to the new total volume in each tube.
iv. As above, each tube should now be a 1:1 mixture of homogenized
sample to the sample buffer.
v. All tubes should also have the exact same volume and consequently,
the same protein concentration.
d. Mix samples thoroughly, and centrifuge to pull all contents down if necessary.
Stacking gel
10. Clean lane combs with 70% ethanol.
11. Prepare the 4% stacking gel in a small beaker with continuous stirring.
a. The volumes8 here are for four 1.5 mm thick 4% polyacrylamide gels.
b. Add 12.2 mL of ddHiO.
c. Add 2.6 mL of Acrylamide solution1; begin to stir.
d. Add 5 mL of Stacking gel buffer5.
e. Add 200 pL 10% SDS3.
f. Let stir for a minimum of 10 min
12. While this is stirring, and separating gel has polymerized, dump the butanol overlay
down the sink and rinse with ddH20.
13. Dry the exposed glass plates (above separating gel) with filter paper.
14. To the partially complete gel, and after 10 min of stirring, add 125 pL of 10% APS
solution (same as previously used) and 25 pL of TEMED simultaneously and let stir
for about 20 seconds.
15. Quickly pour the gel into each cassette with a Pasteur pipet up to the top of the
“short” plate.
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16. Carefully place lane combs in between the two plates, making sure no bubbles are
trapped beneath it.
a. Tip: slide comb in at an angle.
17. Allow gel to polymerize for 30 - 60 min (longer is better).
a. Tip: keep some of the gel in the Pasteur pipet. This will tell you if the gel is
successfully polymerizing.
18. While this is taking place, continue preparing your samples:
a. Bring water in a metal container to about 75 - 80°C, and place samples in
water; maintain this temperature range.
i. Leave samples in hot water for 10 min.
b. Remove from hot water and let cool at room temperature before loading onto
gel.
c. Mix samples again by vortexing, and centrifuge to pull down contents if
necessary.
d. Prepare IX running buffer6 (25 mMTris, 192 mM glycine, 0.1 % SDS) from
10X running buffer if not done so previously, and place in refrigerator. About
1 L is needed per electrophoresis unit.
Gel Loading
19. Once stacking gel has polymerized, carefully remove gel cassettes from apparatus and
transfer to the electrophoresis electrode modules.
a. Each BioRad Mini-Gel Protean Tetra Cell electrophoresis unit holds one
“electrode” module and one “companion” module, and each module holds two
gels. If running only two gels, you must use the “electrode” module.
b. Make sure each cassette is as far down as possible on the modules.
c. Make sure the “short” plate faces the inside of the module.
d. For electrophoresis to work, you need a closed-in compartment on the inside.
If running an odd number of gels, you can place an unused cassette, but with
the “spacer” plate facing the inside, opposite to the lone gel in order to seal off
the inside compartment.
e. Tip: at this point, be sure you can identify your gels.
20. Very carefully remove the lane combs from gel, and fill each well about halfway with
IX running buffer6with a Pasteur pipet.
21. Load the correct amount of each sample into the corresponding wells using a
micropipet (2 - 20 pL or 10-100 pL) with loading tips.
a. If samples were prepared via Method 1 as described above, then each well will
contain different volumes of sample to equalize protein amounts.
b. If samples were prepared via Method 2 as described above, then each well will
contain the same volume of sample as protein concentrations are all the same.
c. If using the BioRadchemiluminescent molecular weight marker (“ladder”;
Precision Plus Protein WestemC Standards #161-0376):
i. Load 3 pL for a 1.5 mm thick gel using the 10-lane comb.
ii. Load 2.5 pL for a 1.5 mm thick gel using the 15-lane comb.
d. If not using a chemiluminescent ladder (BioRad Precision Plus Protein
Standards Kaleidoscope #161-0375 or #161-0324):
i. Load 5 pL for a 1.5 mm thick gel using either the 10-lane or 15-lane
combs.
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22. Fill each well up to the top with IX running buffer6 using a Pasteur pipet.
23. Fill the inside compartment of the electrode modules with cold IX running buffer6 to
a level above the short plate; this covers the wells.
a. Tip: if the volume of the inside compartment drops as you try to fill it, then
there is a leak.
24. Fill the rest of the tank (outside the gel cassettes) with cold IX running buffer6 to the
same level.
25. Optional: remove all bubbles from under the gel cassettes with a syringe pipet.
Electrophoresis
26. Place electrophoresis unit into a second larger container, and cover it with the lid.
a. At this point, ensure that electrodes match on the modules and the lid; i.e.
positive with positive, negative with negative, or red with red, black with black
27. Fill the container with ice.
28. Connect the lid electrodes to the power unit (again red with red, black with black), set
voltage to 150, and press the “run” button.
a. Tip: Higher voltages create more heat which can cause lanes to curve, so
keeping the running buffer6 cold ensures that the lanes remain straight.
29. Allow electrophoresis to occur until the bromophenol blue dye front runs completely
through the gel.
a. It takes about 2 hours with a 10% gel.
30. As this is taking place, and if not done so previously, make transfer buffer7 (25
mMTris, 192 mM glycine, 0.1 % SDS, 20% methanol), and cut filter paper and
nitrocellulose.
a. About 1 L of transfer buffer7 is needed per transfer unit.
b. Cut out 14 pieces of filter paper per transfer unit (7 per “sandwich”) to 7 cm x
10 cm size.
c. Cut out one piece of nitrocellulose per gel to a 6.5 cm x 9 cm size. Be sure to
somehow mark each piece of nitrocellulose to identify the different blots.
31. Put a layer (arbitrary volume) of cold transfer buffer7 into two separate baking dishes.
32. In one dish, soak the nitrocellulose pieces, and in the other soak the filter paper and
Brillo pads.
a. Soak for about 20 min.
b. Aside: This step and length of time is even more important, if not critical,
when using PVDF instead of nitrocellulose.
Transfer
33. Once electrophoresis is complete, and after 20 min of soaking nitrocellulose, unplug
electrophoresis unit, and remove the lid.
34. Very carefully, remove the gels from the electrode modules one at a time.
a. Using the “wedge” piece, separate the short and spacer plates to reveal the gel
itself.
b. With a clean razor, slice off the stacking gel.
c. With the same razor, make small cuts to identify the “top” of the gel, as well as
make markings that match the corresponding pieces of nitrocellulose.
35. Place gels into transfer buffer7 in the same baking dish containing the nitrocellulose
pieces.
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a. Immerse the spacer plate (with gel still adhering to it) into the transfer buffer7
in the baking dish with the nitrocellulose pieces.
b. Using the “wedge” piece, very carefully dislodge each gel from the spacer
plate.
36. Assemble the transfer apparatus (“sandwich”) in the baking dish with the filter paper,
and Brillo pads.
a. Place the “positive” end (white) of the sandwich frame on the bottom.
b. Stack the individual components as follows: 1 Brillo pad, 2 filter papers, 1
nitrocellulose piece, corresponding gel, 3 filter papers, 1 nitrocellulose piece,
corresponding gel, 2 filter papers, 1 Brillo pad. The “negative” end (black) of
the sandwich frame is on top, and secures the sandwich. This can be visualized
in the figure below.

2 gels

1 gel

c. Because the gel is very adhesive to the nitrocellulose in air, it is recommended
to match each piece of nitrocellulose to the corresponding gel while submerged
in transfer buffer7, and then moving them over together to the other dish where
sandwich assembly is occurring.
d. Make sure that the orientation of the gels matches the corresponding pieces of
nitrocellulose. This is far easier to do if you’ve loaded a pre-stained molecular
weight marker.
e. Apply pressure on the sandwich before closing to try to remove bubbles
between the gel and nitrocellulose.
37. Place the closed sandwich in the transfer electrode module, and place this in the
transfer tank.
38. Place an “ice pack” in the tank, and fill the tank with cold transfer buffer7.
a. It is okay to use the same transfer buffer7that was in each baking dish.
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b. A ny portio n o f the gel/nitrocellulose not subm erged in transfer buffer w ill not
transfer.

39. Place transfer unit into a second larger container, and cover the unit with the lid.
a. At this point, ensure that electrodes match on the module and the lid; i.e.
positive with positive, negative with negative, or red with red, black with black
40. Fill the container with ice.
41. Connect the lid electrodes to the power unit (again red with red, black with black), set
voltage to 100, and press the “run” button.
a. Tip: The power unit has trouble maintaining higher voltages if the temperature
of the transfer buffer7 is too high. It is also hard to maintain higher voltages if
there are more than one transfer units plugged into the unit at once.
42. Allow transfer to occur for 70 min.
43. As this is taking place, and if not done so previously, prepare IX Tween TBS8
(TTBS; 10 mMTris pH 7.5, 100 mMNaCl, 0.1% Tween-20) from 10X TBS, and
blocking solution93, b (5% nonfat, dry milk protein93 (for non-phospho proteins) or 5%
BSA9b (for phospho proteins) in TTBS8).
a. Prepare 2 L of TTBS8 for 4 blots.
b. Select small, shallow containers (small Rubbermaid-like containers work well)
for the rest of the incubations of the blots.
c. Depending on the size of the containers, prepare 25 - 30 mL of blocking
solution93’b per container.
d.
Blocking
44. Once transfer is complete, unplug from the power unit and remove the lid from the
transfer tank.
45. Very carefully remove each piece of nitrocellulose and place in the previously
prepared containers with blocking solution9.
a. Tip: if you use a pre-stained molecular weight marker, you can tell that transfer
was successful if the marker is found on the nitrocellulose and no longer found
on the gel.
b. Tip: Use “flat head” tweezers to handle the nitrocellulose and try to only
handle the nitrocellulose pieces from the edges only.
c. Place only two pieces of nitrocellulose (from here on referred to as “blots”) in
each container, and make sure they are in a back-to-back orientation.
46. Allow to incubate for 1 hr at room temperature with gentle shaking (~40 rpm).
a. Be sure to cover each container with parafilm, or a lid if available
47. As this is taking place, prepare the primary antibody solution10,11 (2% nonfat, dry
milk protein10 or 5% BSA 1 in TTBS8+ primary antibodies) in 50 mL Falcon tubes.
a. Make as many tubes as there are containers, and or antibodies.
b. Depending on the size of the containers, prepare 20 - 25 mL of antibody
solution10 per Falcon tube.
c. Allow antibody vials to thaw at room temperature, or on ice if being kept out
of the refrigerator for some time.
d. Pipet into each Falcon tube the appropriate antibody at the correct
concentration
i. GLUT4 - 1:1000 (use “BSA“ primary antibody solution10)
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ii. Insulin Receptor - 1:1000 (use “milk“ primary
antibody solution10)
o
48. When blocking is complete, wash blots once with TTBS .
a. Dump blocking solution9 down the sink and replace with TTBS8 in each
container.
b. Allow to wash for 5 min at room temperature with vigorous shaking (~90 rpm).
Primary Antibody
49. Dump TTBS8 down the sink and replace with the previously prepared antibody
solution10, u .
50. Allow blots to incubate overnight (1 2 -1 6 hours) at 4°C (refrigerator) with gentle
shaking (~60 rpm).
a. Be sure to cover each container with parafilm, or a lid if available.
51. Before primary antibody incubation is stopped, prepare the secondary antibody
solution (2% nonfat, dry milk protein in TTBS + horseradish peroxidase (HRP)conjugated secondary antibodies) in 50 mL Falcon tubes.
a. It is best to use new Falcon tubes every time; however they can be reused if
necessary if washed thoroughly (eg. with soap, bleach, and 70% ethanol).
b. Make as many tubes as there are containers, and or antibodies.
c. Depending on the size of the containers, prepare 20 —25 mL of antibody
solution per Falcon tube.
d. Pipet into a Falcon tube BioRad #170-6515 goat pAb anti-rabbit IgG HRP
conjugate - 1:10000
e. If using the chemiluminescent ladder, and if visualization of it is desired, also
pipet into each Falcon tube the BioRad Precision Protein StrepTactin-HRP
conjugate (#161-0380) at a 1:15000 dilution.
52. Once primary antibody incubation is done, remove any unbound primary antibody
with three successive washes and rinses in TTBS8.
a. Dump the primary antibody solution10,11 in each container down the sink, and
pour a volume (unspecified) of TTBS into each container.
b. Allow washing to occur for 10 min at room temperature with vigorous shaking
(~90 rpm).
c. Dump out first volume of TTBS8 and do a quick rinse of the blots with new
TTBS8.
d. Dump out the “rinse” TTBS8 and replace with a third volume of TTBS8
(second wash).
e. Repeat this process for a total of 3 washes.
Secondary Antibody
o
53. Dump TTBS down the sink and replace with the previously prepared secondary
antibody solution12.
54. Allow blots to incubate for 60 min at room temperature with gentle shaking (~40
rpm).
a. Be sure to cover each container with parafilm, or a lid if available.
55. As this is taking place, and if not done so previously, prepare IX Tris buffered
saline13 (TBS; 10 mMTris pH 7.5, 100 mMNaCl) from 10X TBS.
a. Prepare 100 mL of TBS13 for 4 blots (2 containers).
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56. Once secondary antibody incubation is done, remove any unbound secondary
antibody with successive washes and rinses in TTBS8.
a. Dump the secondary antibody solution12 in each container down the sink, and
pour a volume (unspecified) of TTBS8 into each container.
b. Allow washing to occur for 10 min at room temperature with vigorous shaking
(~90 rpm).
c. Dump out first volume of TTBS8 and do a quick rinse of the blots with new
TTBS8.
d. Dump out the “rinse” TTBS8 and replace with a third volume of TTBS8
(second wash).
e. Repeat this process for a total of 3 washes.
57. After the last TTBS8 rinse, perform one final rinse with the previously prepared
TBS13 and leave blots in a volume (unspecified) of TBS13.
a. Be sure to cover each container with parafilm, or a lid if available.
b. Tip: Tape down the parafilm cover (if not using a lid) with masking tape, as
blots will soon be transported.
c. If not imaging right away, place blots in 4°C (refrigerator). Be sure to image
within a few days.
Chemiluminescent imaging
58. Be sure you have the following at the Chemidoc XRS system station:
a. Your blots (in TBS13), “flat head” tweezers, BioRadlmmun-Star
WesternCchemiluminescense kit (#170-5070), 1000 pL pipet and tips (at least
3 per blot), 1.5 mL Eppendorf tubes (at least 1 per blot), overhead
transparencies (at least 1 per blot), Kimwipes, 70% ethanol, USB key,
parafilm, scissors, masking tape, and gloves.
b. Tip: Cut each transparency in half.
59. Turn on the BioRadChemidoc XRS System, open the Quantity One 1-D analysis
program, and insert your USB key into the computer.
a. Within Quantity One, select the “band analysis guide” from the toolbar, and a
pop-up with a list of items should appear on the top right of the screen.
b. Click on the “select scanner” button, and select the “Chemidoc XRS” from the
subsequent pop-up.
c. A control window should open up. Click on the “Live/Focus” button in this
window, and press the “Epi White” button on the chemidoc system itself.
60. Open up the drawer of the chemidoc, and clean the inside surface with 70% ethanol.
61. Prepare the BioRadchemiluminescence substrate in a 1.5 mL Eppendorf tube.
a. Pipet 500 pL of the Luminol/enhancer solution and 500 pL of the peroxide
solution into the Eppedorf tube, and mix contents well (eg. vortex).
b. 1 mL of the final solution (500 pL + 500 pL) is plenty for one blot.
62. Remove one of your blots from the TBS13, drain/shake off some of the TBS13, and
place the blot face up on one transparency (or half of one if you’ve cut it).
63. Pipet onto your blot the chemiluminescence solution, making sure to fully, and
evenly, cover your blot (or at least the area where you expect your bands to show up).
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64. Place a second transparency (or the other half if you’ve cut one) on top of your blot,
and try to press away any bubbles that may have formed between the blot and
transparencies.
65. Place the blot “sandwich” on the chemidoc drawer so that the blot is approximately in
the center, and close the drawer.
66. Open the top door of the Chemidoc, and align your blot so that’s in the center of the
camera’s field of view.
a. First, center your blot manually (reach in and move it).
b. Once centered, zoom in and focus on the blot, using the buttons in the Quantity
One control window.
c. It is best to zoom in as much as possible; your bands should take up the entire
width of the camera’s field of view.
67. In the control window in Quantity One, check the “highlight saturated pixels” box
near the bottom, and click on the “Open Iris” button repeatedly.
a. Saturated pixels will be displayed red, and there should be a “pulsating” ellipse
of red pixels in the center of the display.
b. Continue pressing this button until the size of the ellipse is no longer
noticeably increasing.
68. Close the Chemidoc door, and press the “Epi White” button again to turn off the light.
69. Click on the “Freeze” button in the control window in Quantity One, and then click
on the “Live Acquire” button in the same window.
a. A pop-up appears, in which you can decide exposure parameters.
b. Choose the total time of exposure, the time it takes for the first image capture,
and the total number of image captures.
c. Tip: 600 seconds (10 min) total exposure time is adequate.
70. Allow the camera to detect the chemiluminescence for the total exposure time.
a. Out of the images that are captured as exposure is taking place, select at least
one to analyze.
b. Tip: It is best to choose an image in which your bands of interest are just on the
verge of saturation.
c. Tip: Hopefully you’ve done the Western Blot with the right conditions in order
to achieve saturation towards the end of the 10 minutes of exposure; longer
time to saturation is better.
71. Once finished, remove blot from chemidoc, clean the drawer surface with 70%
ethanol again, and repeat the process with the rest of the blots.

Solutions
Name

1.

Acrylamide
solution

Components,
concentrations,
pH
Acrylamide 30% (w/v)
Bis-acrylamide -

Example
amounts

Storage

Acrylamide 150 g
Bis-acrylamide -

4°C
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0.8% (w/v)
2.

Separating
gel buffer

3.

SDS
solution

4.

2X
Laemmli
SDS-PAGE
sample
buffer

5.

6.
7.

8.

9.

T ris- 1.5 M
SDS - 0.4 %
(w/v)
pH -8 .8
SDS-10%
(w/v)

4g
Total V - 500
mL
Tris - 90.9 g
SDS - 2 g
Total V- 500 mL

T ris-0.125 M
Glycerol - 20%
(v/v)
SDS - 4%

S D S - 10 g
Total V - 100
mL
Tris - 7.57 g
Glycerol —100
mL
SDS - 20 g

P~

P-

mercaptoethanol
mercaptoethanol
-10% (v/v)
- 50 mL
Bromophenol
Bromophenol
blue-0.015%
blue - 0.075 g
(w/v)
Total V - 500
pH -6 .8
mL
Stacking
Tris - 0.5 M
Tris - 30.3 g
gel buffer
SDS - 0.4%
SDS - 2 g
(w/v)
Total V - 500
pH -6 .8
mL
10X
Tris - 0.25 M
Tris - 60.6 g
running
Glycine - 1.92
Glycine - 288 g
buffer
M
S D S -20 g
SDS - 1% (w/v)
Total V - 2 L
IX running
1OX running
10 X running
buffer
buffer - 10%
buffer - 100 mL
(v/v)
Total V - 1 L
IX transfer
10X running
10X running
buffer
buffer - 10%
buffer - 100 mL
(v/v)
Methanol - 200
Methanol - 20%
mL (add last)
(v/v)
Total V - 1 L
10X TBS
Tris - 0.1 M
Tris - 24.2 g
NaCl- 1 M
NaCl - 116.9 g
pH - 7.5
Total V - 2 L
IX TTBS
10X TBS -10%
10X TBS-200
(v/v)
mL
Tween-20 Tween-20 - 2
0.1% (v/v)
mL
pH -7 .5
Total V - 2 L
Blocking_______a. Non-fat, dry______ a. Non-fat, dry

4°C

Room
temperature
Room
temperature,
fumehood

4°C

4°C

4°C

4°C or
colder

Room
temperature
Room
temperature

Room
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solution

Primary
antibody
solution 1

Primary
antibody
solution 2

Secondary
antibody
solution

IX TBS

milk protein 5% (w/v)
b. Bovine serum
albumin - 5%
(w/v)
IX TTBS - 95%
Non-fat, dry
milk protein 2% (w/v)
IX TTBS - 98%
Antibody against
protein of
interest
Bovine serum
albumin - 5%
(w/v)
IX TTBS - 95%
Antibody against
protein of
interest
Non-fat, dry
milk protein 2% (w/v)
IX TTBS-98%
Antibody against
primary antibody
1OX TBS - 10%
(v/v)
pH - 7.5

milk protein 1.25 g
b. Bovine serum
albumin - 1.25 g
IX T TB S-top
up to 25 mL
Non-fat, dry
milk protein 0.4 g
IX T TB S-top
up to 20 mL

temperature

Bovine serum
albumin - 1 g
IX TTBS-top
up to 20 mL

4°C (-20°C
long term)

Non-fat, dry
milk protein 0.4 g
IX TTBS-top
up to 20 mL

Room
temperature

10X TBS - 10
mL
Total V - 100
mL

Room
temperature

4°C (-20°C
long term)

'
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Separating Gel Formulations'^
15 % Gel
2 gels

4 gels

6 gels

8 gels

ddH20

4.663 mL

9.325 mL

13.988 mL

18.65 mL

Acrylamide
solution1

10 mL

20 mL

30 mL

40 mL

Separating gel
buffer2

5 mL

10 mL

15 mL

20 mL

SDS solution3

200 pL

400 pL

600 pL

800 pL

10% APS solution

125 pL

250 pL

375 pL

500 pL

TEMED

12.5 pL

25 pL

37.5 pL

50 pL

Total Volume

20 mL

40 mL

60 mL

80 mL

2 gels

4 gels

6 gels

8 gels

19.988 mL

26.65 mL

12 % Gel
13.325 mL

ddH20

6.663 mL

Acrylamide
solution1

8 mL

16 mL

24 mL

32 mL

Separating gel
buffer2

5 mL

10 mL

15 mL

20 mL

SDS solution3

200 pL

400 pL

600 pL

800 pL

10% APS solution

125 pL

250 pL

375 pL

500 pL

TEMED

12.5 pL

25 pL

37.5 pL

50 pL

Total Volume

20 mL

40 mL

60 mL

80 mL

2 gels

4 gels

6 gels

8 gels

10% Gel
ddH20

7.996 mL

15.992 mL

23.988 mL

31.984 mL

Acrylamide
solution1

6.667 mL

13.333 mL

20 mL

26.667 mL

Separating gel
buffer2

5 mL

10 mL

15 mL

20 mL

SDS solution3

200 pL

400 pL

600 pL

800 pL

10% APS solution

125 pL

250 pL

375 pL

500 pL

TEMED

12.5 pL

25 pL

37.5 pL

50 pL

Total Volume

20 mL

40 mL

60 mL

80 mL
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7.5 % Gel
2 gels

4 gels
19.325 mL

6 gels

8 gels

28.988 mL

38.65 mL

ddH20

9.663 mL

Acrylamide
solution1

5 mL

10 mL

15 mL

20 mL

Separating gel
buffer2

5 mL

10 mL

15 mL

20 mL

SDS solution3

200 pL

400 pL

600 pL

800 pL

10% APS solution

125 pL

250 pL

375 pL

500 pL

TEMED

12.5 pL

25 pL

37.5 pL

50 pL

Total Volume

20 mL

40 mL

60 mL

80 mL

2 gels

4 gels

6 gels

8 gels

31.988 mL

42.65 mL

6 % Gel
ddH20

10.663 mL

Acrylamide
solution1

4 mL

8 mL

12 mL

16 mL

Separating gel
buffer2

5 mL

10 mL

15 mL

20 mL

SDS solution3

200 pL

400 pL

600 pL

800 pL

10% APS solution

125 pL

250 pL

375 pL

500 pL

TEMED

12.5 pL

25 pL

37.5 pL

Total Volume

20 mL

40 mL

60 mL

80 mL

4 gels

6 gels

8 gels

17.975 mL

23.967 mL

Stacking Gel Formulation
4 % Gel

21.325 mL

'

50 pL

Q

2 gels
ddH20

5.992 mL

11.983 mL

Acrylamide
solution1

1.333 mL

2.667 mL

4 mL

5.333 mL

Stacking gel buffer5

2.5 mL

5 mL

7.5 mL

10 mL

SDS solution3

100 pL

200 pL

300 pL

400 pL

10% APS solution

62.5 pL

125 pL

187.5 pL

250 pL

TEMED

12.5 pL

25 pL

37.5 pL

50 pL

Total Volume

10 mL

20 mL

30 mL

40 mL
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PROTOCOL RENEWAL FORM

Protocol # 2008-095 Noble

I. All animals used in this research project will be cared for in accordance with the recommendations of the Canadian
Council on Animal Care and the requirements of the provincial legislation entitled, 'The Animals for Research Act," of the
Province of Ontario.
II. I confirm that this Animal Use Protocol accurately represents the proposed animal use.
III. I accept responsibility for procedures performed on animals in this project.
IV. I will ensure that any individual who will perform any animal-related procedure(s) within this protocol will complete all
related mandatory training AND will be made familiar with the contents of this document.
1. I support the above declaration * YES
T ew s
le smsnission of this form and its electronic delivery to auspc@uwo.ca
2. By checking ‘YES’ in this section, I
YES S NOD
AUS APPROVAL - AUS Office Use Only Signature:
Veterinary Authorization by Click Here
Authorization Date (mm/dd/yy) l /
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Pick One Only-

E3 I confirm that NO CHANGES and/or NEW ELEMENTS to this AUP - other than staffing - have occurred since the last AUS
Form submission.
□ I confirm that all CHANGES and/or NEW ELEMENTS to this protocol not previously submitted WILL BE sent via a
Protocol Modification form along with this Protocol Renewal Form.
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THE UNIVERSITY OF WESTERN ONTARIO - ANIMAL USE SUBCOMMITTEE

PROTOCOL RENEWAL FORM

Protocol # 2008-095 Noble

Describe any progress made with respect to the Three R's of replacement, reduction and refinement of animal usé during
the P A ST P R O TO C O L YEAR. See the CCAC 3 R ’s M icrosite; http://www.ccac.ca/en/alternBtives/
__________ _

We have used less animals than anticipated in the past year because we have made
oflhl^sues gjjrated by the animals
that we employed.___________________________________ ____________ ______________________________________
EU

No additional anim als were used during the past Protocol Year.;
No additional anim ais were requested during the past Protocol Year,

Describe any complications beyond the expected experimental outcomes and end points encountered relative to animal
use - e.g. unpredicted outcomes and any unexpected animal pain, distress, or mortality - AND indicate measures being
undertaken to resolve these complications for the PAST P R O TO CO L YEAR.
E3 No complications were encountered relative to animal use during the past Protocol Year.

Choose One of the Following Statements:
1. Analgesics were administered as outlined within the
currently used below:

Analgesics are not indicated in this

Anim al Use Protocol

□ *lf checked, please list all analgesics

Anim al Use Protocol
_______________________________ ___________________________
TRAINING INFORMATION

C C A C Mandated Training Requirements — AN personnel working with live animals require CCAC mandated training including the ‘Basic

Animal Care & Use Web-CT Course’and related hands-on Workshops'.

1Basic Animal Care & Use

Completion of the
W eb-CT CourseJonce
every 5 years is mandatory for ALL personnel, including the Principal Investigator. The Animal Use Subcommittee will be informed of all
personnel with incomplete training beyond 1 month of notice.
Workshop Enrolment Detail — The Workshop' requirements are determined by the species and procedures associated with each individual
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PROTOCOL RENEWAL FORM

Protocol # 2008-095 Noble

listed below. All personnel listed below will be contacted directly via the email address listed below for auto-enrolment in all 'Workshop'
requirements. Previous hands-on ‘ Workshops* attended at another research institution may be accepted; please submit training documentation
with this form. For additional training requirement detail and associated costs, go to
H Q Q I

¡¡¡¡1 1 1 1
PROCEDURES PER S P E C IE S

FIRST
NAME

LAST
NAME

Repeat
For
Each
Species
Used

Repeat
For
Each
Species
Used

ROLE

(Role
within this
Protocol)
Researcher
Staff
Student

EMAIL
Address

HANDS
ON

*Mandatory
Field*

Animal
Work?

UWO&
Affiliated
Institution
Emails
Preferred

YES

or

NO

SPECIES
One
Species
Per Row

Use an
Additional
Row for
Each
Species

1=Basic Handling
2=Health Monitoring
3=Blood Collection
4-Injections
5=Anaesthesia
6=Surgery-Recovery
7=Surgery-Non-Recovery
8=Euthanasia/Post Mortem
9=Other, Provide D etail Below, e.g. suturing

Expected
STA R T
D A TE

mm/dd/yy

2

3

4

5

6

7

8

El

El

El

El

El

El

El

El

El

El

El

□

El

E
E E

El

El

El

El

□

El

El

□

El

El

El

El

□

El

El

□

«ëstaki@ uvjn: I
11/01/09
Rat
El E l El El El □ El
a ÆÊ I
l^utwftcUjHer implantation of insulin pellets is necessary (EN and TD only); gavage for ginseng

El

E

1

Earl

Noble

Tomasz

Dzialoszyns
ki

Staff

Oscar

Campos

Student

Jordan

Silver

Student

Mehrbod

Researcher enoble@uwo.ca^

Estaki

Student

PROCEDURE #9 DETAIL

EMERGENCY AFTER HOURS
CONTACT NAMES & NUMBERS
- NO LAB PHONE NUMBERS If applicable, provide POST-OP
CARE personnel detail
If applicable, provide MONITORING
personnel detail

\

tdzialos@u^d^
a "WL
ocampos@uW^k

■ 1/01 /09

YeM

11/01/09
11/01/09

i^Kjes

Rat

IE R G E N C Y C O N T A C T
. I N I T I A L : N o b le E

îc o n d a r y T m e r g e n c y C O N T A C T
'L A S T N A M E & IN IT IA L : D z ia lo s z y n s k i T
S a m e a s E m e r g e n c y C o n t a c t, o r

te:

11/01/09

e
e
e
El

PRIMARY EMERGENCY CO N TACT
NUMBER (HOME OR CELL) : 519-472-8399
SECONDARY EMERGENCY CO N TA CT
NUMBER (HOME OR C E L L ): 519-472-7371
Em ergency #:519-472-8399 L a b # : 88373 Em ail:
enoble@ uw o.ca

>am e a s E m e r g e n c y C o n t a c t, o r

E m e rg e n c y # :519-472-8399 L a b # : 88373 Email:
e n o b t e @ u w o .c a

la m e :
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B.2 Climbing Apparatus

